Document:

EX-10.27

 Exhibit 10.27 

COMMERCIAL AGREEMENT 
 Dated as of
February 1, 2011 
 by and between 
 Syngenta
Crop Protection AG 
 Schwarzwaldallee 215 
 P.O. Box 

CH-4002 Basel 
 Switzerland 

(hereinafter referred to as “SYT”) 

and 
 Marrone Bio Innovations, Inc. 

2121 Second Street 
 Suite B-107 

Davis 
 CA 95618 

USA 
 (hereinafter referred to as “MBI”)

 Each a “Party” and collectively the “Parties” 

* * * * * * * * 
 Relating to
Biological Crop Protection Products 
 WHEREAS 

MBI has available the biological fungicide Regalia Maxx 20% for agricultural uses and other products under development; 

SYT has a broad crop protection product portfolio and a highly developed distribution network all over Europe, Africa and the Middle East; 

Gaining access to the Commercial Product of MBI can allow SYT to strengthen innovative crop programs in particular in the area of specialty
crops; 
 Gaining access to the SYT distribution network and sales and marketing expertise can provide a unique possibility for MBI to reach
the markets in Europe, Africa and the Middle East. 
 NOW THEREFORE, the Parties agree as follows: 

  

	 	1.	Definitions, Interpretations and Exhibits 

 In this Commercial Agreement (including the preamble) the
following capitalized terms shall have the meanings assigned to them below: 
  

			
	“Additional Countries”	  	shall mean Turkey, Morocco, Israel, South Africa and Egypt;
		
	“Affiliate”	  	 any business entity which controls, is controlled by or is under common control with either Party; for the purpose of this definition, a business entity shall be
deemed to “control” another business entity if it owns, directly or indirectly, in excess of 50% of the outstanding voting securities or capital stock of such business entity or any other comparable equity or ownership interest with
respect to a business entity other than a corporation;

		
	 “Annual Business Meeting”
 and future
business and the
	  	 shall mean a yearly meeting of both Parties to discuss current resolution of any potential operational and contractual issues;

	“Bulk”	  	 shall mean ISO tanks of [*****] or other substantially similar bulk packaging;

		
	“Business Plan”	  	 is an agreed document outlining the yearly SYT sales (in volume) to its customers based on an agreed Registration Plan and is attached hereto as Exhibit
1;

		
	“COGS”	  	 of the Commercial Product shall mean all costs and expenses which are directly attributable to the manufacture of the Commercial Product, which include the costs
to purchase raw materials or finished or semi-finished products, energy and utilities required to manufacture the Commercial Product and direct labour costs of the employees and toll manufacturing costs, but exclude costs for selling, distribution,
advertising or research and development;

		
	“Commercial Agreement”	  	 shall mean this supply, distribution and development agreement for the Commercial Product signed between the Parties;

		
	“Commercial Product”	  	 shall mean Regalia Maxx 20% and it’s Product Enhancements, ready for sale;

		
	“Contract Year”	  	 shall mean the period of consecutive twelve months from January 1st in any given year to December 31 of the
same calendar year;

		
	“Delivery Date”	  	 shall have the meaning ascribed to it in Sections 4.1 and 11;

		
	“Effective Date”	  	 shall mean the date of signature of the Commercial Agreement by both Parties;

		
	“EPPO Zonal Countries”	  	 shall mean the United Kingdom, France and Poland;

		
	“Exclusivity”	  	shall mean the exclusive commercial rights for the Commercial Product in the Field in the Territory granted from Effective Date of the Commercial Agreement by MBI to
SYT;

  

	[*****]	Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

  
 2 

			
	“Field”	  	 shall mean the use of Commercial Product for agricultural uses in Specialty Crops [*****];

		
	“Force Majeure”	  	 shall mean blockade, civil commotion, earthquake, explosion, fire, flood, general army mobilization, insurrection, lightning, revolution, riot, sabotage, storm,
war (declared or undeclared) and any similar cause which is not reasonably within the control of the Party affected. For the avoidance of doubt, events and circumstances within each Party’s responsibility, such as breakdown of a plant due to
inability to hire sufficient and qualified staff shall not be deemed to constitute Force Majeure;

		
	“Forecast”	  	 shall mean [*****] rolling forecast by SYT of quantities to be purchased as further described in Section 4 and Exhibit 4;

		
	“Good Faith”	  	 All negotiations between the parties have to be led in Good Faith;

		
	“Hardship”	  	 Shall mean the case if either the price of Reference Products drops a specified percent or more in a [*****] (or a specified percent over [*****] consecutive
years) and/or the COGS increase by a specified percent or more in a [*****] (or a specified percent over [*****] consecutive years); all as described in Section 6;

		
	“Key Crops”	  	 shall mean [*****],

		
	“Lead Countries”	  	 shall mean Spain, Italy and France;

		
	“Milestone Countries”	  	 shall mean UK, Spain, Italy and France;

		
	“Milestone Payments”	  	shall mean payments from SYT to MBI upon reaching milestones in preparation of the Registration of the Commercial Product, as further described herein;
		
	“Predevelopment Product”	  	shall mean products for agricultural use developed by MBI, which are on the path to being, but are not yet, a development product but for which the following have been
completed: 1) rat limit test, 2) initial chemistry, 3) patent filed, 4) positive glasshouse efficacy, and 5) can be fermented consistently at 1 liter scale;
		
	“Order”	  	 shall mean a written and binding order for the purchase of Commercial Product;

		
	“Party”	  	 shall mean any one of the parties hereto and “Parties” shall mean both of them;

		
	“Price”	  	shall mean the price at which MBI sells Commercial Product to SYT as set forth in, and subject to adjustment as provided in, Exhibit 5;
		
	“Price Adjustments”	  	shall mean the annual adjustment of the Price for the Commercial Product;

  

	[*****]	Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

  
 3 

			
		
	“Product Enhancements”	  	shall mean any improvements and enhancements of the Commercial Product containing Reynoutria plant extract as an active ingredient, with enhanced features and properties including new
formulations and other concentrations, that MBI has or obtains the right to Register and sell in the Field in the Territory; but not including combinations with other active ingredients;
		
	“Reference Products”	  	shall mean three leading products proposed by SYT which are used in the Field in the three Lead Countries, as further described in Exhibit 5;
		
	“Registration”	  	shall mean the permissions, authorizations, registrations or approvals, from applicable regulatory authorities that are necessary to develop, sell, formulate or distribute a
pesticide product for uses in the Field in a specified jurisdiction. For the avoidance of doubt, Registration, in Section 7 of this Commercial Agreement, refers to the Registration of the Commercial Product’s active ingredient (including, but
not limited to, the inclusion of the Commercial Product’s active ingredient in Annex I of the EU Directive 91/414/EC and EC 1107/2009) as well as of end-use Commercial Product containing such active ingredient. The term to “Register”
shall be construed accordingly;
		
	“Registration Plan”	  	is an agreed to document outlining the target Registrations by crops and countries and is attached hereto as Exhibit 2;
		
	“Registration Steering Team”	  	 shall mean a team of regulatory, technical and commercial people from both Parties who meet regularly to discuss status, progress and remedies that may be required
towards the goal of achieving desired country Registrations and assessing the potential effects on the Business Plan;

		
	“Specifications”	  	 the technical and quality specifications for the Commercial Product set forth in Exhibit 3, as amended from time to time by agreement in writing between the
Parties hereto. The Specifications shall adequately describe the physical and chemical properties (such as e.g. particle sizes) of the Commercial Product. Exhibit 3 shall also contain the testing method for ascertaining compliance of the Commercial
Product with the Specifications;

		
	“SYT Group of Companies”	  	 shall mean any entity under the ultimate common control of Syngenta AG;

		
	“Territory”	  	 shall mean EAME as further specified in Exhibit 6;

		
	“Trademarks”	  	 shall mean the trademarks of the “SYT Group of Companies”;

		
	“USD”	  	shall mean United States Dollars;

  
 4 

 The Section headings contained in this Commercial Agreement are for reference purposes only and
shall not affect in any way the meaning or the interpretation of this Commercial Agreement. 
 The Exhibits shall constitute an integral part
of this Commercial Agreement. In the event of any conflict between any of the Exhibits and the Commercial Agreement, the Commercial Agreement shall prevail. 

2.     Purpose and Commitment 

2.1 Subject to the terms and conditions set forth herein, MBI intends to collaborate in researching, developing and Registering the Commercial Product and SYT in
evaluating, marketing and selling biological crop protection products in Europe, Africa and Middle East (EAME). 
 2.2 Subject to the terms and conditions set
forth herein, SYT will be the exclusive distributor of the Commercial Product for use in the Field in the Territory and MBI will exclusively supply the Commercial Product for use in the Field in the Territory to SYT. 

2.3 SYT is committed to pre-invest a total amount of USD [*****] from 2011 until 2013 to prepare the platform for the launch of the Commercial
Product. For the development and for the technical pre-launch and the market research SYT shall invest additionally USD [*****]. 
 2.4 SYT
shall invest these amounts directly and in addition to the marketing and sales expenses necessary to reach the Business Plan targets. 
 2.5
During the year 2010 SYT is already testing the Commercial Product in Key Crops under the terms of the Material Transfer Agreement signed between the Parties in April 29, 2008. 

3.     Exclusive Distribution 

3.1 Subject to the terms and conditions hereof, MBI agrees to sell to SYT the Commercial Product and SYT agrees to purchase all of its
requirements of the Commercial Product from MBI and distribute the Commercial Product for use in the Field in the Territory. 
 3.2
Notwithstanding anything to the contrary contained herein, Italy will be excluded from the Territory until March 1, 2011, and shall be included in the Territory thereafter. 

3.3 Notwithstanding anything to the contrary contained herein, Turkey and Israel will not be included in the Territory for the time being, as MBI
has informed SYT about prior existing commitments in Turkey and Israel. Both Parties will agree within 6 months after signing of this Commercial Agreement how SYT exclusive distribution rights in Turkey and Israel can be granted and automatically
included in the Territory under the terms of this Commercial Agreement; provided, further, that if after 24 months after signing of this Commercial Agreement such exclusive distribution rights have not been obtained with respect to either country or
countries then such country or countries will not be included in the Territory and the Registration and Business Plan will be amended accordingly. 

3.4 Upon completion by SYT of initial commercial sales (commercial sales considered to be completed when first invoice to a SYT customer is
issued) of the Commercial Product for use in the Field in a country within the Territory hereunder, MBI will discontinue the sales of Rey-

  

	[*****]	Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

  
 5 

 
noutria active ingredient formulations in such respective country; provided, however, that MBI may sell off existing inventory or work in progress of such product in such country. 

3.5 SYT shall use commercially reasonable efforts to develop sales and achieve targets agreed in the Business Plan attached hereto as Exhibit 1.

 3.6 If at any time the sales targets set forth in the Business Plan are not met by SYT for any [*****] as a whole, MBI shall have the right to [*****] of
the Commercial Product and any other Reynoutria active ingredient formulation in the Territory (the “Section 3.6 [*****] Right”), while all other terms of this Agreement not in conflict with this Section 3.6 shall remain unchanged;
provided, however, that if the Section 3.6 [*****] Right is triggered and the right to [*****] is prohibited by law or regulation or judicial order in any country in the Territory, then MBI shall provide SYT with [*****] if MBI [*****] in such
country and then SYT`s rights to purchase and distribute Commercial Product and any other Reynoutria active ingredient formulation in such country in the Territory under this Commercial Agreement shall immediately terminate (provided that MBI shall
continue to supply the Commercial Product to SYT for a reasonable period of time as necessary to satisfy SYT’s obligations to its existing customers). 

3.7 If at any time the binding forecasted purchase volumes for the first four quarters as described in Section 4.1 are below [*****] of [*****] of the
previous year and sales targets set forth in the Business Plan are not met, MBI shall have the right to [*****] of the Commercial Product and any other Reynoutria active ingredient formulation in the Territory (the “Section 3.7 [*****]
Right”); provided, however, that if the Section 3.7 [*****] Right is triggered and the right to [*****] is prohibited by law or regulation or judicial order in any country in the Territory, then, [*****] from MBI, SYT`s rights to purchase
and distribute Commercial Product and any other Reynoutria active ingredient formulation in such country in the Territory under this Commercial Agreement shall immediately terminate (provided that MBI shall continue to supply the Commercial Product
to SYT for a reasonable period of time as necessary to satisfy SYT’s obligations to its existing customers). 
 3.8 Both Parties agree to
meet annually prior to September 15 of each year, starting in 2011, for the Annual Business Meeting. Participants attending the Annual Business Meeting shall be selected by each Party individually and may be changed at the discretion of such
Party. 
 3.9 SYT shall at all times under this Commercial Agreement be regarded as an independent contractor and shall purchase the Commercial
Product on its own account for resale to third parties. 
 4     Exclusive Supply 

4.1 SYT shall submit [*****] rolling Forecasts with a [*****] for the [*****]. SYT shall submit an updated version of the rolling Forecast every
quarter of the Contract Year in the first ten working days of the month of the respective quarter. The rolling Forecast submitted shall be confirmed by MBI within 10 working days after receipt. After MBI’s confirmation such Forecast shall be
binding for the first four quarters for both Parties. The first quarter of each rolling Forecast shall be split into monthly sections. Scheduled Delivery Dates in SYT’s Orders for Commercial Product purchased hereunder shall be no less than 60
days before the expected Delivery Date. 

  

	[*****]	Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

  
 6 

 4.2 All Orders shall be governed exclusively by the terms and conditions of this Commercial Agreement, and any terms
or provisions on any SYT Order forms that are inconsistent with those contained in this Commercial Agreement shall have no force or effect whatsoever as between the Parties. Neither MBI’s commencement of performance nor delivery shall be deemed
or construed as acceptance of SYT’s additional or different terms and conditions. Orders may be sent by facsimile transmission or email or, if approved by MBI, other electronic media and shall set forth the exact quantity of Commercial Product
required and the requested Delivery Date. Provided that each Order is given in accordance with this Commercial Agreement, the requested Delivery Date shall be binding on MBI. Orders for the Commercial Product must be in Bulk. 

4.3 Subject to the terms and conditions hereof, MBI shall manufacture (or have manufactured) and supply Commercial Product in Bulk according to
the Specifications and the Orders to SYT. The Commercial Product shall be supplied to SYT FOB delivery port of departure Atlantic Coast of the US in accordance with Incoterms 2010 (as published by the International Chamber of Commerce). 

4.4 MBI shall supply such quantity of Commercial Product to SYT as SYT may order, subject to the maximums in the binding Forecasts, in accordance
with the terms of this Commercial Agreement. MBI shall make available the required production capacity at MBI’s facility or a facility of a third party to comply with SYT’s Orders and the requested Delivery Date for the Commercial Product.
In the event that Syngenta requires additional volumes above the agreed current quarter Forecast, with respect to Commercial Product supplied, MBI shall use commercially reasonable efforts to supply such volumes, but shall not have any obligation to
fill any Order to the extent that it exceeds one hundred twenty five percent (125%) of the forecasted orders for such Commercial Product as set forth in the Forecast. Syngenta retains a right to visit, after mutual agreement, the contracted
manufacturing and storage facilities of MBI subject to a reasonable prior notice. 
 4.5 MBI shall inform SYT immediately when it becomes aware
of a possible delay in the supply of Commercial Product. In such case the Parties shall jointly discuss possible solutions to minimize damages caused through late delivery. 

4.6 Should MBI not be able to supply the requested capacity of Commercial Product to SYT, in accordance with the Forecasts and Orders duly
submitted in accordance with this Commercial Agreement, in the aggregate for a period of one year, then the Parties shall jointly discuss in Good Faith possible commercially reasonable solutions. 

4.7 Both Parties shall comply at all times with applicable law regarding the delivery, storage, production, supply etc. of the Commercial
Product. 
 4.8 Transfer of full title as well as risk of loss or damage to the Commercial Product shall occur in accordance with the chosen
Incoterm (Incoterms 2010) as specified in this Section 4. 
 5     Price and Payment 

5.1 The Price per unit at which SYT may purchase Commercial Product are set forth on Exhibit 5. All Prices are in United States Dollars. 

5.2 Commencing in 2012, the Price shall be [*****], based on publicly available price variation of the [*****] in the jointly agreed three [*****]. 

  

	[*****]	Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

  
 7 

 5.3 Price [*****] shall begin with the [*****] of the [*****] and will continue for the duration of the Commercial
Agreement in accordance with the Price [*****] process specified in Exhibit 5. 
 5.4 Invoices may be issued by MBI from any country outside Switzerland at any
time after the FOB delivery. 
 5.6 MBI shall invoice SYT for each delivery made. 

5.7 Payment for each delivery shall be due within [*****] of the date of MBI’s invoice. 

6     Hardship 

6.1 In the event of Hardship, the Price shall be adjusted as provided herein. If (a) the price of Reference Products drops by [*****] or
more in a [*****] or [*****] or more over [*****] consecutive years, and/or (b) the COGS increases by [*****] or more in a [*****] or by [*****] or more over [*****] consecutive years; then the Price shall be adjusted to reflect such changes in
such other prices or COGS and to maintain as near as reasonably possible SYT’s competitive status in the market and MBI’s margins. The Party claiming the adjustment of the Price due to Hardship shall provide sufficient proof to show the
triggering values are reached. Hardship adjustments shall apply also for Product Enhancements. 
 6.2 In case the adverse Party decides that
the proof provided by the Party claiming the adjustment is not satisfactory, an external auditor or appropriate expert, agreeable to both Parties, shall examine the proof and any supporting materials upon request of the adverse Party. If the expert
confirms correctness of the claim, the dissenting Party shall have to cover the costs. Should the expert conclude that a price adjustment was due but the claim was not in line with the adjustment due, the costs shall be split between the Parties
fifty-fifty. In case the expert concludes that no claim was due the claiming Party shall have to bear the costs of the expertise. The auditor’s assessment shall be final and binding upon the Parties. 

7     Product Registration and Milestone Payments 

General 
 7.1 Subject to the terms and conditions hereof, MBI
shall Register the Commercial Product for use in the Field in the Territory in the EPPO Zonal Countries, in the Milestone Countries and the Additional Countries, as provided below and according to the agreed Registration Plan and Business Plan. 

7.2 Subject to the terms and conditions hereof, MBI shall obtain, as provided below, and use its commercially reasonable efforts to maintain Registrations of the
Commercial Product, in accordance with the Registration Plan and the Business Plan, until the expiration or termination of this Commercial Agreement. MBI shall solely own such Commercial Product Registrations except as may be otherwise provided in
this Commercial Agreement. 
 7.3 SYT shall make Milestone Payments to MBI. These payments shall be made in consideration of the upfront costs incurred by MBI
and for the exclusivity granted to SYT under this Commercial Agreement. SYT shall pay MBI the amount of USD [*****] in each of the [*****] upon reaching the applicable milestones as per Exhibit 2. 

  

	[*****]	Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

  
 8 

 7.4 Should MBI fail to timely achieve the Registrations in accordance with the Registration Plan, the Business Plan
shall be amended accordingly. For the avoidance of doubt, failure to obtain or maintain any Registrations of the Commercial Product shall not be a material breach of this Commercial Agreement but shall result in a Business Plan amendment as
necessary. 
 7.5 SYT will provide MBI with Commercial Product trial data that SYT has generated for use to support Registration and commercial decisions for
the Commercial Product 
 7.6 SYT may be consulted on the Registration approach for Registering the Commercial Product. SYT will assist MBI in the Registration
process where possible with SYT’s existing resources and expertise. For this purpose, a Registration Steering Team will be established by and between both Parties. 

Registration in the European Union 
 7.7 It is understood by
MBI and SYT that, consistent with the requirements of the European Union (Regulation (EC) No 1107/2009), that MBI will prepare and submit the active ingredient dossier to obtain the active ingredient approval in the EU and prepare and submit the
Commercial Product dossier, which addresses the full regulatory requirements for national authorisation in the three EPPO Zonal Countries including any national specific regulatory studies and risk assessments. This should be useful in achieving in
principal the Registration of the Commercial Product in the three respective EPPO zones. Subject to the terms and conditions hereof, MBI shall Register the Commercial Product in the three EPPO Zonal Countries. 

MBI agrees to prepare and submit 2 additional Commercial Product dossiers with respect to Registration in all four (4) Milestone Countries, in accordance
with the Registration Plan and the Business Plan and, subject to the terms and conditions hereof, MBI shall use its commercially reasonable efforts to Register the Commercial Product in the four Milestone Countries. 

In the event additional country specific Registration or other regulatory requirements are required in any EU member states (other than the EPPO Zonal
Countries), or other significant costs or efforts are required beyond the ones specified in the Registration Plan and the Business Plan, or herein, SYT and MBI technical and commercial people will discuss in Good Faith options to obtain desired
Registration of the Commercial Product. The Parties shall jointly assess and discuss eventual adverse findings and difficult outcomes to obtain and maintain such Registrations. MBI and SYT shall both use commercially reasonable efforts to obtain any
such desired Registrations; provided, however, that if MBI, after reasonable time and the previously described consultation decides in writing not to continue or pursue any such Registration, then SYT may take over the cost and responsibility for
obtaining such Registration and shall reimburse MBI for incremental costs incurred to date in connection with such efforts by MBI (such costs to be reasonably documented). Incremental costs shall include costs which are incurred with respect to a
specific country in connection with Registration. In the event SYT takes over the responsibility from MBI, reimburses MBI and bears the additional Registration costs, SYT will be the owner of the Registration in that EU member state. If SYT does not
wish to reimburse MBI for such costs, but decides to pursue Registration in the respective country then SYT and MBI will jointly own the Registration in such EU member state (in recognition of the contribution of both Parties). 

Registration in other Countries of the Territory 
 7.8 In
addition, MBI agrees to prepare five (5) Commercial Product dossiers in accordance with the Registration Plan and the Business Plan in connection with the Registration of the 

  
 9 

 
Commercial Product in the Additional Countries. Subject to the terms and conditions hereof, MBI shall use its commercially reasonable efforts to Register the Commercial Product in these five
countries. In the event significant costs or efforts are required beyond that specified in the Business Plan, the Registration Plan or herein with respect to any of these Registrations, SYT and MBI technical and commercial people will discuss in
Good Faith options to obtain desired Registration of the Commercial Product. The Parties shall jointly assess and discuss eventual adverse findings and difficult outcomes to obtain and maintain such Registrations or amend the list of Additional
Countries by mutual agreement. MBI and SYT shall both use commercially reasonable efforts to obtain any such Registrations; provided, however, that if MBI, after reasonable time and the previously described consultation decides in writing not to
continue or pursue any such Registration, then SYT may take over the cost and responsibility for obtaining such Registration and shall reimburse MBI for incremental costs incurred to date in connection with such efforts by MBI. In the event SYT
takes over the responsibility from MBI, reimburses MBI and bears the additional Registration costs, SYT will be the owner of the Registration in that country. If SYT does not wish to reimburse MBI for such costs, then SYT and MBI will jointly own
the Registration in such country (in recognition of the contribution of both Parties). 
 7.9 Should SYT wish to Register the Commercial Product in [*****] of
the Territory [*****], SYT shall inform MBI in writing of its intent. Thereafter MBI shall inform SYT within [*****] whether MBI wishes to undertake commercially reasonable efforts to obtain such Registrations. Should MBI decline to undertake such
efforts to Register the Commercial Product in such [*****], SYT may [*****] such Registration and shall [*****] connection with such efforts and SYT [*****] the Registration in that country. 

7.10 Should MBI wish to Register the Commercial Product in [*****] of the Territory [*****], MBI shall inform SYT in writing of its intent. Thereafter SYT shall
inform MBI within [*****] whether SYT wishes to undertake commercially reasonable efforts to market and sell the Commercial Product in that country based on a business plan. Should SYT decline to undertake such efforts in such [*****], or fail to
make substantial steps in furtherance of such efforts, MBI shall have the right to Register the Commercial Product in [*****] and [*****] of the Commercial Product and any other Reynoutria active ingredient formulation in [*****] the Territory. All
other terms of the Commercial Agreement shall in this case remain unaffected. 
 Registration Issues 

7.11 In some jurisdictions it may be necessary or desirable for Registrations otherwise to be owned by MBI hereunder to be in the name of SYT, an affiliate of
SYT or some local entity that may be affiliated with SYT. In such event, the Parties agree that such Registrations shall nonetheless be transferred to MBI upon MBI’s request or otherwise relinquished upon MBI’s request. 

7.12 All Registrations under this Agreement shall reference the SYT Trademark(s) and MBI as the manufacturer, as further specified in Section 8 below. 

8     Trademarks 

8.1 SYT will register and solely own the Trademarks under which SYT shall sell the Commercial Product hereunder. SYT will propose such Trademarks
for the Commercial Product to MBI, and MBI shall have one month to approve or object to SYT’s proposal. Keeping silent shall mean consent. MBI will not withhold its approval without material rea

  

	[*****]	Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

  
 10 

 
son. In the event of objection by MBI, SYT and MBI shall jointly discuss possible changes or alternatives. All rights and costs related to the registration and maintenance of the Trademarks will
be borne by SYT. In case of a discontinuation of the distribution of the Commercial Product, SYT will retain any and all rights related to the Trademarks. 

8.2 SYT shall solely be responsible for the labelling of the packed Commercial Product. The labelling shall be done in accordance with the
applicable rules for labelling and Registration as well as with the applicable national laws. MBI’s company name will be listed on the package in accordance with regulations. 

8.3 SYT shall use reasonable efforts to maintain and safeguard its Trademarks and interests and shall take all reasonable steps to defend the
Trademarks including, the prosecution of any actions which SYT may reasonably deem desirable to commence for the protection of any of its rights. If necessary, MBI will provide SYT with commercially reasonable assistance in connection with such
efforts at SYT’s expenses. 
 8.4 MBI shall promptly bring to the attention of SYT any improper or wrongful use of any of the Trademarks
in the Territory that comes to its notice. 
 8.5 All rights and goodwill relating to the Trademarks owned by SYT Group Companies shall remain
the property of SYT Group Companies at all times. 
 8.6 No Party shall under any circumstances be allowed to use any Trademarks or similar
designation of the other Party as part of its corporate name or on its business cards or letterheads. 
 8.7 Trademarks, service marks or any
trade secrets or proprietary information of any kind that are proprietary to one of the Parties are and shall forever remain the sole property of that Party, and may not be used by the other for any purpose other than carrying out its
responsibilities hereunder. 
 8.8 SYT shall sell the Commercial Product in the packaging and with the labels as chosen by SYT and under the
Trademarks of a SYT Group Company. MBI shall use commercially reasonable efforts to assist SYT in assuring that the packaging and labels of the Commercial Product conforms to the Commercial Products’ Registration and all applicable laws and
regulations in the Territory. 
 9     Intellectual Property 

9.1 Each Party’s rights in its intellectual property shall not be affected by the Commercial Agreement unless otherwise specified herein.

 9.2 Subject to the terms and conditions set forth herein, MBI retains all copyright, patent, trade secret, trademark rights and other intellectual property
rights in and to the Commercial Product. Nothing in this Commercial Agreement is intended to create ownership by SYT in the intellectual property rights of MBI. 

9.3 Without limitation to any of the rights and obligations elsewhere in this Commercial Agreement, in case a patentable invention made by one
party is not severable from confidential Information received from the other Party, that inventing/patenting Party shall grant the other Party a royalty-free, worldwide, non-exclusive license for the use of such patented invention. 

  
 11 

 9.4 MBI shall be obliged to inform its licensor KHH Biosci, Inc., North Carolina, about this
Commercial Agreement entered with SYT in writing. A copy of the respective letter shall be sent to SYT. 
 10     Health
and Safety - Responsible Care 
 10.1 MBI shall provide SYT with Material Safety Data Sheets or other similar safety and health
information, including, without limitation, warnings, precautionary safety measures, and instructions on proper care, use and handling, storage, and disposal of the Commercial Product. 

10.2 MBI and SYT shall abide by sound health, safety and environment (HSE) principles. They agree to communicate openly on HSE issues which may
have shown up and to work together to ensure long-term safe and secure handling, storage and disposal of the Commercial Product. Meetings to review business improvement may include HSE assessments. 

10.3 Both Parties and its employees and customers shall follow safe handling, storage, transportation, use, and disposal practices with respect
to the Commercial Products in accordance with the safety, health and environment standards of the industry and the label requirements. 
 10.4
In case there is any legislation change regarding the use of the Commercial Product in the Territory, the provisions of this legislation change shall overrule the terms of this Commercial Agreement and SYT shall follow all applicable national and
international legislation for the Commercial Product in the Territory. MBI and SYT shall inform each other on new legislation that might affect the use of the Commercial Product in the Territory of which they become aware. 

11     Acceptance; Limited Warranty 

11.1 SYT shall have fifteen (15) days following receipt of each shipment of the Commercial Product at the FOB point in which to notify MBI
in writing of any discrepancies in such shipment as to quantity, quality, weight, loss or damage to the Commercial Product. Such SYT written notice to MBI shall specify in reasonable detail the nature and basis of the claim and cite relevant control
numbers or other information to enable identification of the shipment in question. MBI shall use commercially reasonable efforts to correct such discrepancies after being so notified. If SYT fails to give such written notice within fifteen
(15) days, such shipment of Commercial Product will be deemed accepted. 
 11.2 MBI warrants to SYT that all Commercial Product sold to SYT pursuant to
this Commercial Agreement shall conform to the Specifications for a period of 24 months from and after the date of delivery to SYT at the FOB point. Conformity with the Specifications shall be determined by reference to the method of analysis set
forth in the Specifications. 
 11.3 Subject to the limitations set forth herein, upon discovery of any failure of any Commercial Products to
conform to the Specifications, SYT shall promptly contact MBI, and MBI shall promptly replace or remedy such Products at MBI’s expense. MBI shall be responsible for all freight and insurance charges associated with any such replacement (and any
reasonable charges in connection with any necessary return or disposal of nonconforming Product); provided, however, that if MBI’s inspection discloses that the returned Commercial Products or any other Commercial Products in connection with
which a warranty claim is made are not defective within the terms of the warranty provided herein, then SYT shall pay such freight and insurance and disposal charges associated with such replacement, return and disposal. MBI shall not be liable
under any warranty set forth herein with respect to any Commercial 

  
 12 

 
Products that fail to conform to the Specifications if, and to the extent, such failure would have been avoided but for misuse, neglect, alteration, improper storage or improper testing of the
Commercial Products by SYT or its customers. 
 11.4 If SYT and MBI are unable to agree as to whether Commercial Product fails to conform to
the Specifications within the terms of the warranty provided herein, the Parties shall cooperate to have Commercial Product in dispute analyzed by an independent testing laboratory of recognized repute selected by MBI and approved by SYT, which
approval shall not be unreasonably withheld. The results of such laboratory testing shall be final and binding on the Parties on the issue of compliance of Commercial Product with Specifications within the terms of the warranty provided herein. If
Commercial Products are determined to have complied with such warranty, then SYT shall bear the cost of the independent laboratory testing. If Commercial Product is determined to not to have complied with such warranty, then MBI shall bear the costs
of the laboratory testing, and SYT shall have the warranty recourse afforded under Section 11.3. 
 11.5 The Warranty set forth herein is
the only warranty, express or implied, that MBI makes with respect to the Commercial Product. 
 11.6 MBI shall for a period of at least
thirtyy-six (36) months after the manufacture of Commercial Products keep all records and samples concerning each batch of the Commercial Products, except for any such records and samples that MBI reasonably believes would not be relevant for
the determination of conformity of the Commercial Products with the Specifications; provided, that in the event Syngenta delivers notice of a defect (including a hidden defect), MBI shall maintain all such records and samples then in MBI’s
possession related to the applicable batch of Commercial Products until resolution of such claim. 
 12     Use
Extension 
 12.1 Subject to the terms and conditions hereof, SYT shall have the exclusive option to extend the Field of use of the
Commercial Product to flowers and ornamentals as well as to the use in seed treatment in the Territory. Such option shall be exercisable by [*****] the Parties [*****] prior to [*****] (within 12 months after signature of the Memorandum of
Understanding (MOU) signed between the Parties on [*****]. 
 12.2 Should MBI decide to start Registration trials to support the extension of the Field of use
of the Commercial Product to agricultural crop uses in the Territory, MBI shall promptly notify SYT of such Registration trials. SYT shall have 30 business days after receipt of such notification to confirm in writing its interest in testing the
Commercial Product for such additional agricultural uses in the Territory. Subject to the terms and conditions hereof, from the day SYT communicates its interest in such extension, a 12 months exclusive testing period starts during which SYT shall
have the exclusive right (along with MBI) to test the Commercial Product for such additional agricultural crop uses in the Territory. Within this 12 months testing period, SYT shall have the exclusive option, exercisable by written notice to MBI, to
enter into exclusive commercial negotiations with MBI regarding the extension of the agricultural crop uses of the Commercial Product in the Territory. As soon as SYT exercises this option, a 6 months exclusive commercial negotiation period starts
where both Parties negotiate in Good Faith the commercial terms of an extension to SYT of exclusive distribution rights of the Commercial Product for the new crop uses in the Territory. SYT agrees that such distribution shall occur pursuant to a
Business Plan and a Registration Plan for the additional crop uses similar to the one covering the use of the Commercial Product herein. 

  

	[*****]	Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

  
 13 

 12.3 Subject to the terms and conditions hereof, during a period of 12 months after the Effective Date of this
Commercial Agreement SYT shall have a non-exclusive option to negotiate the extension of the Territory of this Agreement. The NAFTA countries are not part of this option. If SYT exercises this non-exclusive option, both Parties agree to negotiate in
Good Faith comparable terms to those included in this Commercial Agreement, including possible additional milestone payments for Registrations in the additional Territories. 

12.4 Should SYT not timely exercise any of the exclusive options mentioned herein, MBI shall be free to offer the Commercial Product for other uses, for extended
agricultural crop uses and in countries which are not part of the Territory to third parties. 
 13     Product
Enhancements 
 MBI shall notify SYT of any Product Enhancements of the Commercial Product that MBI makes generally commercially available. Such Product
Enhancements will be added in writing to this Commercial Agreement as an additional Commercial Product. The other terms of this Commercial Agreement shall remain unchanged, provided, however, prices may change if use rates change. 

14     Access to Predevelopment Products 

14.1 Prior to becoming a development product, a product must pass through MBI’s pre-development stage. During the term of this Commercial Agreement, MBI
shall notify SYT of existing Predevelopment Products as of the Effective Date and, as soon as reasonably practical, and not later than any other third party, of each new available Predevelopment Product, its specifics, the crops with which it can be
used (if known) and the field of application. SYT shall have [*****] after receipt of such notification to confirm to MBI in writing its interest in testing such Predevelopment Product. Subject to the terms and conditions hereof, from the date of
SYT’s written notice of interest to test, SYT shall have a [*****] testing period with respect to such Predevelopment Product. Notwithstanding anything to the contrary contained herein, Predevelopment Products shall exclude any product or
candidate that has proceeded to the Predevelopment Product stage within MBI as a result of a separate discovery and development agreement with another third party. 

14.2 Within this [*****] testing period, SYT shall have the opportunity, exercisable by written notice to MBI, to enter into exclusive commercial negotiations
(the “Negotiation Option”) regarding the Predevelopment Product with MBI in the Territory if at the time of receipt of such notice MBI has not entered into exclusive commercial negotiations with any other third party with regard to such
Predevelopment Product. As soon as SYT exercises this Negotiation Option, a [*****] commercial negotiation period starts where both Parties negotiate in Good Faith the terms regarding the commercial exploitation of the Predevelopment Product in the
Territory. SYT agrees that such exploitation shall occur pursuant to an agreement including a Business Plan and a Registration Plan and Milestone Payments and shall include an exclusivity fee for any exclusive agreement. 

14.3 The nonexclusive testing by SYT of the Predevelopment Product terminates upon the earlier of (i) when a Commercial Agreement between the Parties is
executed, or (ii) the expiration of the [*****] negotiation period. 
 15     MBI Liability 

15.1 MBI agrees to hold harmless and indemnify SYT against all claims and liabilities (including all costs incident to any suit and judgment
including without limitation reasonable attor-

  

	[*****]	Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

  
 14 

 
ney’s fees and investigation cost) made against SYT except where and to the extent caused by SYT’s gross negligence or wilful misconduct and except where damages sum up to less than USD
[*****] as a result of (i) MBI’s noncompliance with any applicable law relating to the performance by MBI of the terms of this Commercial Agreement (ii) MBI’s breach of the terms of this Commercial Agreement. 

15.2 The obligation to provide indemnification in Section 15.1 is contingent upon (a) the indemnified party giving prompt written
notice to the indemnifying party of any such claim, action or demand, (b) the indemnified party allowing the indemnifying party to control the defense through an attorney reasonably satisfactory to the indemnified party, and related settlement
negotiations, and (c) the indemnified party fully assisting in the defense so long as the indemnifying party pays the indemnified party’s out-of-pocket expenses. 

15.3 Except for a Party’s breach of the intellectual property rights under Section 9 or the confidentiality obligations under
Section 17 or gross negligence or wilful misconduct, neither Party shall have any liability, whether based in contract or tort, for any punitive, exemplary, consequential, special, indirect or incidental loss of profits or interruption of
business, arising from or related to this Commercial Agreement. 
 15.4 MBI agrees to comply in all respects with the “Minimum
Requirements for SYT suppliers” as further specified in Exhibit 8. 
 15.5 During the term of this Commercial Agreement MBI shall all
times keep up product liability insurance. SYT shall have the right to ask for a written proof that such insurance agreement has been concluded. 

16     SYT Responsibilities and Liability 

16.1 SYT shall market, sell and distribute the Commercial Products at SYT’s risk and on SYT’s own account. In correspondence and other
dealings relating directly or indirectly to the sale or other disposition of the Commercial Products, SYT shall indicate that it is acting on its own account. 

16.2 SYT shall be responsible to sell and distribute Commercial Product only in accordance with the Commercial Product Registrations. 

16.3 SYT agrees to hold harmless and indemnify MBI against all claims and liabilities (including all costs incident to any suit and judgment
including without limitation reasonable attorney’s fees and investigation cost) made against MBI except where and to the extent caused by MBI’s gross negligence or wilful misconduct and except where damages sum up to less than USD [*****]
as a result of (i) SYT’s non-compliance with any applicable law relating to the performance by SYT of the terms of this Commercial Agreement (ii) SYT’s breach of the terms of this Commercial Agreement. 

16.4 The obligation to provide indemnification in Section 16.3 is contingent upon (a) the indemnified party giving prompt written
notice to the indemnifying party of any such claim, action or demand, (b) the indemnified party allowing he indemnifying party to control the defense through an attorney reasonably satisfactory to the indemnified party, and related settlement
negotiations, and (c) the indemnified party fully assisting in the defense so long as the indemnifying party pays the indemnified party’s out-of-pocket expenses. 

16.5 Except for a Party’s breach of the intellectual property rights under Section 9 or the confidentiality obligations under
Section 17 or gross negligence or wilful misconduct, neither Party shall have any liability, whether based in contract or tort, for any punitive, exemplary, 

  

	[*****]	Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

  
 15 

 
consequential, special, indirect or incidental loss of profits or interruption of business, arising from or related to this Commercial Agreement. 

16.6 SYT agrees to comply in all respects with the “Minimum Requirements for SYT suppliers” as further specified in Exhibit 8 

17     Confidentiality 

17.1 The Parties shall hold in strict confidence all confidential or proprietary information and data disclosed by or on behalf of the other or
its Affiliates prior to or after execution of this Commercial Agreement (collectively, “Information”) and the Parties shall not use such Information for any purpose other than the manufacture, supply and distribution of the Commercial
Product and the performance of its other duties under this Commercial Agreement. The Parties shall not disclose such Information to third parties, without the other Party’s prior approval in writing. 

17.2 The Parties shall only disclose the Information to those of its own and its Affiliates’ officers, employees, board members and
consultants with a need to know for the proper performance of the duties under this Commercial Agreement and shall take all commercially reasonable steps to assure that all members of its staff to whom disclosure is made will observe the above
obligations. Neither Party shall disclose such Information to any existing or potential shareholder who is a direct competitor of the other Party. 

17.3 The above confidentiality obligations shall not apply to Information which: 

 

	 	(i)	 Parties can prove by written evidence was in its possession prior to disclosure by or on behalf of the other or its Affiliates; or

  

	 	(ii)	 on the date of first disclosure to one of the Parties by or on behalf of the other Party or its Affiliates was in the public domain or thereafter
becomes part of the public domain by publication or otherwise, except by one Party’s breach of this Commercial Agreement; or 

  

	 	(iii)	 which one of the Parties may receive from a third party, provided, however, that such information was not obtained by such third party, directly or
indirectly, from a Party to this Commercial Agreement or its Affiliates; or 

  

	 	(iv)	 which a Party may have to disclose to the competent regulatory bodies in order to obtain and/or maintain the manufacturing, distribution and other
licences and authorisations necessary for the manufacture, supply and distribution of the Commercial Product. 

 17.4 The Parties agree that
the terms of this Commercial Agreement, its exhibits and all related discussions will be treated as confidential. Provided, however, that nothing herein shall prohibit disclosure of the existence of this Commercial Agreement to existing or potential
investors or compliance by MBI with applicable securities laws. 
 17.5 The obligation to confidentiality shall outlive this Commercial Agreement for a term of
six years to be calculated starting from Termination or expiration of this Commercial Agreement. 
 18     Term and
Termination 
 18.1 This Commercial Agreement shall become effective on the Effective Date. 

  
 16 

 18.2 The term of this Commercial Agreement shall be 5 years calculated separately for each country
of the Territory, starting from the first sales of Commercial Product in the Field in the respective country. Notwithstanding the foregoing, the term of this Commercial Agreement shall expire on the date that is fifteen (15) years after the
date of the first Registration of the Commercial Product in the Territory. 
 18.3 The Commercial Agreement shall not be automatically renewed,
but the Parties will meet two years prior to expiration of the Commercial Agreement in order to consider the renewal of the Commercial Agreement in Good Faith. 

18.4 Notwithstanding the foregoing, either Party may terminate this Commercial Agreement with immediate effect by giving notice of termination to
the other Party: 
  

	 	(i)	 upon any material breach of this Commercial Agreement by the other Party which is not remedied within sixty (60) days from notification thereof;

  

	 	(ii)	 upon the other Party committing an act of bankruptcy or compounding with its creditors or being confiscated or sequestrated or nationalised or in any
other way transferred into state ownership; 

  

	 	(iii)	 SYT shall have the right to terminate the Commercial Agreement with a 30 day notice period should Exclusivity hereunder not be granted in Italy,
Turkey or Israel within 24 months after the Effective Date of the Commercial Agreement. 

 18.5 Either Party may forthwith
terminate this Commercial Agreement in writing if the other Party has been prevented from fulfilling its obligations under this Commercial Agreement, in whole or in part, for more than one hundred eighty (180) days due to a Force Majeure event.

 18.6 In the event a petition for relief under any bankruptcy law or legislation is filed by or against MBI, or MBI makes an assignment for
the benefit of creditors or a receiver is appointed for all or a substantial portion of MBI’s assets, and such petition, assignment or appointment is not dismissed or vacated within thirty (30) days, then the Parties shall jointly discuss
in Good Faith possible commercially reasonable solutions regarding the supply of Commercial Product to SYT. 
 18.7 Upon the expiration or termination of this
Commercial Agreement, any Registrations (but excluding any Trademarks of SYT) to be owned by MBI hereunder or jointly owned by MBI hereunder that may be in the name of SYT, an affiliate of SYT or some local entity that may be affiliated with SYT, or
otherwise not in the name of MBI, shall nonetheless be transferred to MBI upon MBI’s request or otherwise relinquished upon MBI’s request at no additional cost to MBI. 

18.8 Upon the expiration or termination of this Commercial Agreement, any Registrations (but excluding any Trademarks of SYT) to be owned by SYT hereunder or
jointly owned by SYT hereunder, shall nonetheless be transferred to MBI upon MBI’s request or otherwise relinquished upon MBI’s request, and MBI shall pay SYT for such transfer an amount to be negotiated between the Parties in Good Faith
reflecting the value of the business including the transferred Registrations at the time of such transfer. 
 19
    Force Majeure 
 19.1 In the event that either Party is affected by any circumstance that prevents the fulfilment
by such Party of its obligations hereunder in whole or in part, then such Party shall notify the other Party of the nature and extent of such circumstance(s), as promptly as possible. 

  
 17 

 19.2 Neither Party shall be deemed to be in breach of this Commercial Agreement, or otherwise be
liable to the other Party, by reason of any delay in the performance, or non-performance, of any of its obligations hereunder to the extent that such delay or non-performance is due to Force Majeure of which it has notified the other Party and the
time for the performance of such obligation shall be extended accordingly. The Party so affected shall take all reasonable steps to minimise the loss occasioned to the other Party and the Parties shall as soon as practicable enter into bona fide
discussions with a view to alleviating the effects of said circumstance or to agreeing upon such alternative arrangements as may be fair and reasonable. 

19.3 Upon cessation of the Force Majeure, the Party affected by Force Majeure shall resume the performance of its contractual obligation(s), as
promptly as possible, unless such performance has been waived in writing by the Party to whom such performance was due. 
 19.4 Should the
Force Majeure event lead to an interruption in the supply of Commercial Product to SYT hereunder for more than ninety (90) days, then the Parties shall jointly discuss possible commercially reasonable solutions. 

20     Miscellaneous 

20.1 This Commercial Agreement shall supersede all prior oral or written agreements between MBI and SYT or its Affiliates in relation to the
subject matter hereof including the Memorandum of Understanding signed between the Parties on October 27, 2010 (the “MOU”) and such MOU shall herewith terminate and be of no further force or effect. 

20.2 This Commercial Agreement may be amended only in writing signed by both Parties, and any provision of this Agreement may be waived only in
writing signed by the party waiving compliance. 
 20.3 Any assignment of this Commercial Agreement, in whole or in part, by either Party shall
require the written prior consent of the other Party, except that either Party is entitled to assign this Commercial Agreement to an Affiliate, successor in interest or purchaser of all or substantially all of its assets, provided that (i) the
assignor undertakes to inform in writing the other Party as soon as reasonably possible and (ii) the assignee undertakes in writing to be bound by the same rights and obligations as contained herein. 

20.4 All notices provided required under this Commercial Agreement shall be in the English language and in writing and shall be given by
registered letter, facsimile or e-mail to the addresses set forth below, or such other address as either Party may communicate to the other Party in accordance with this Section. A notice shall be deemed to be received upon actual receipt of a
registered letter (as evidenced by the respective receipt) or on the first business day following the date of transmission if sent by facsimile or e-mail. 

If to SYT: 
 Syngenta Crop Protection AG 

EAME Legal Department 
 Schwarzwaldallee 215 

CH-4002 Basel 
 Switzerland 

Fax: [*****] 
 If to MBI: 

  

	[*****]	Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

  
 18 

 Marrone Bio Innovations, Inc. 

Pam Marrone 
 2121 Second Street 

Suite B-107 
 Davis, California 95618 

USA 
 Fax: 530-750-2808 

20.5 The Parties agree that any public press release to announce this Commercial Agreement will be agreed to by both Parties (such agreement not
to be unreasonably withheld or delayed). 
 20.6 In the event any provision of this Commercial Agreement is deemed to be void under any
applicable law, the remaining provisions of this Commercial Agreement shall not be affected and the void provision shall be deemed to have been replaced by such valid and enforceable provision which most closely reflects the original intention of
the Parties. 
 20.7 Failure of either Party to enforce at any time any of the provisions of this Commercial Agreement, irrespective of any
previous action or proceeding taken by it, shall in no way be considered: 
  

	 	(i)	 a waiver of such provisions: 

	 	(ii)	 to affect the validity of this Commercial Agreement; or 

	 	(iii)	 to preclude or prejudice the Party from exercising the same or any other rights it may have under this Commercial Agreement. 

21     Governing Law and Jurisdiction 

21.1 This Commercial Agreement shall be governed by and construed in accordance with the laws of Switzerland, excluding the principles of
conflict of laws and the United Nations Convention on the International Sale of Goods. 
 21.2 All disputes arising out of this Commercial
Agreement shall be settled by binding arbitration, in accordance with the Rules of the International Chamber of Commerce by an arbitration tribunal consisting of three arbitrators, who are to be appointed in accordance with said rules. The language
of the arbitration proceedings shall be English, and the place of arbitration shall be Zurich, Switzerland. 
 22
    Taxes; Import; Export; Exchange Approvals 
 22.1 All foreign, federal and state taxes based upon SYT’s
purchase, use, sale, distribution or possession of the Commercial Product, other than United States income or franchise taxes payable by MBI, will be borne and paid by SYT. MBI agrees to furnish any documents to taxing authorities if reasonably
requested to do so by SYT. 
 22.2 SYT shall be responsible for obtaining import licenses, export licenses, currency exchange approvals and any
other governmental approvals in or outside the Territory that may be necessary to permit the sale of and payment for the Commercial Product ordered by SYT for distribution and resale within the Territory. SYT shall comply with any and all laws,
regulations or orders that govern or affect the ordering, export, shipment, import, sale, deliver and redelivery of Commercial Product in the Territory and shall furnish MBI with such documentation as MBI may request to confirm SYT’s compliance
with the provisions of this Section 22. 

  
 19 

 
SYT shall not engage in any course of conduct that would cause SYT or MBI to be in violations of the laws of any jurisdiction, including the US foreign corrupt practices act. 

23     Directly Competitive Products 

SYT shall notify MBI in writing at least [*****] by SYT in the Territory of any biological product for use in the Field which could be directly
competitive to the Commercial Product. Upon receipt of such notice, MBI shall have the option, upon [*****] written notice to SYT, to re-negotiate the terms and conditions of this Commercial Agreement, such re-negotiated terms and conditions not to
be less favorable than terms and conditions offered by MBI to any similarly situated third party. 
 [signature page follows] 

  

	[*****]	Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

  
 20 

 IN WITNESS WHEREOF, the Parties hereto have caused this Commercial Agreement to be duly executed as
of the date first set forth above. 
  

							
	Place: Davis	 		 	Place: Basel	 	
				
	Marrone Bio Innovations Inc.	 		 	Syngenta Crop Protection AG	 	
				
	/s/ Pam Marrone	 		 	/s/ Hans Gut	 	  

	 Pamela Marrone
 President and CEO
	 		 	 Hans Gut
 Head Third Party EAME CP
	 	
				
	Date:	 		 		 	
	  
	 		 	/s/ Sibylle Oser	 	  

	  
	 		 	 Sibylle Oser
 Legal Counsel EAME CP
	 	  

				
	  
	 		 	Date: February 21st, 2011	 	  

  
 21 

 Exhibits to the Commercial Agreement: 

1)   Business Plan 
 2)
  Registration Plan and Milestone Payment Plan 
 3)   Commercial Product Specifications 

4)   [*****] rolling forecast model (empty) 

5)   Pricing & Reference Products 

6)   List of EAME Countries 

7)   List of Specialty Crops 

8)   Minimum Requirements for SYT suppliers 

  

	[*****]	Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

  
 22 

 Exhibit 1: Business Plan 

[*****] 

  

	[*****]	Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

  
 23 

 Exhibit 2: Registration Plan and Milestone Payment Plan 

a)   Registration Plan 

[*****] 
 Every month of delay to
reach a Milestone leads to an equal monthly delay in payment of the respective Milestone Payment. 

  

	[*****]	Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

  
 24 

 Exhibit 3: Commercial Product Specifications 

[*****] 

  

	[*****]	Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

  
 25 

 Exhibit 4: [*****] Rolling Forecast Model 

[*****] 

  

	[*****]	Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

  
 26 

 Exhibit 5: Pricing & Reference Products 

1) Pricing 
 a)   Initial Price 

The initial Price per unit at which SYT may purchase Commercial Product shall be USD [*****]. 

It is anticipated that the use rate will range from min. [*****], with the assumption that the [*****]. Within one month of the first country
regulatory submission, the Price will be determined on the [*****] in the Key Crops of tomatoes, lettuce and cucumber in the first country of Registration. However, the Price will not be less than USD [*****]. 

Examples: 
  

	 	•	 	 use rate of [*****] the initial Price will be USD [*****] 

	 	•	 	 use rate of [*****] the initial Price will be USD [*****]. 

b)   Price Adjustments 

[*****] 
 2)   Reference Products

 [*****] 
 Farm prices
indicated are the average prices (equally weighted) for the three Lead Countries. 
 Either of the Parties shall be free to suggest to the
other Party at any time in writing a review of the Reference Product list for substantial reasons (e.g. new product concept). If no agreement is reached between the Parties after six (6) months, each Party can ask for arbitration and both
Parties agree to accept the final and binding decision of the arbitrator. 

  

	[*****]	Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

  
 27 

 Exhibit 6: List of EAME Countries (the “Territory”) 

[*****] 

  

	[*****]	Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

  
 28 

 [*****] 

Notwithstanding anything to the contrary contained herein, “Territory” shall not include any country to which or in which MBI would be
prohibited from directly or indirectly selling or shipping Commercial Product under any US law, regulation or order. 

  

	[*****]	Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

  
 29 

 Exhibit 7: List of Specialty Crops 

[*****] 

  

	[*****]	Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

  
 30 

 Exhibit 8: Minimum Requirements for SYT Suppliers 

 

	 	1)	Introduction 

 SYT has committed to upholding the principles set out in the Universal Declaration of Human
Rights of the United Nations and the International Labour Organization’s Core Conventions. These include: freedom of association; the right to organize and collective bargaining; non-discriminatory remuneration; and minimum working age. The
core conventions forbid practices such as unlawful discrimination, child labour, bonded labour and slavery. 
 This document is based on the key rules and
regulations which apply within SYT and which implement the above commitments which are specified in detail in articles 22 to 24 of the SYT Code of Conduct. This document forms an integral and binding part of the contractual relationship between the
respective SYT Group Company and your company (the “Supplier”). 
  

	 	2)	Freedom of Association and Collective Bargaining 

 Where recognized in accordance with local laws, MBI
shall recognize unions and collective worker representations for collective bargaining and negotiation purposes regarding the terms and conditions of employment. 

No employee or employee representative of MBI must be subject to discharge, discrimination, harassment, intimidation or retaliation for exercising his or her
lawful right to associate or bargain collectively. 
  

	 	3)	Working Hours / Wages & Benefits / Conditions of Work 

 The regular working hours of MBI’s
employees must not exceed any limits defined by local laws. If there are no local laws requiring overtime payments, MBI must follow ILO regulations which require that any working hours in excess of 48 during any workweek must be voluntary and must
be compensated at one and one quarter times the employee’s regular rate. 
 All employees of MBI must receive a wage no less than the national minimum
wage. 
 MBI shall ensure that all employees work in a safe environment at all premises under MBI’s control. 

MBI shall comply with all applicable environmental rules, obligations and laws applicable to the operations at MBI’s premises. 

 

	 	4)	Child Labour 

 MBI must not use any child labour. Child labour is considered any work or activity that
interferes with the full time schooling of a child and/or is mentally, physically, socially or morally dangerous and harmful to children. In addition, MBI must not employ children younger than the legal minimum working age for children, and must not
employ young person’s to undertake dangerous or hazardous work. 
  

	 	5)	Discrimination 

 MBI shall ensure that hiring, placement, remuneration, advancement, training and
disciplinary decisions within MBI are consistent with local law. If there are no local laws prohibiting discrimination in the workplace, Supplier agrees not to make any employment decisions on an individual’s gender, age, nationality,
ethnicity, race, colour, creed, caste, language, disability, organizational membership, opinion, health status, marital status, maternity, sexual orientation, or the employee’s civic, social, or political distinctiveness. 

  
 31 

	 	6)	Illegal, Forced, Bonded & Compulsory Labour 

 MBI must not use or benefit from any illegal labour,
including illegal migrant labour, nor will MBI use or benefit from any forced, compulsory and/or bonded labour. 

  
 32EX-10.28

 Exhibit 10.28 

COMMERCIAL AGREEMENT 
 Dated as of
August 26, 2011, 
 by and between 
 FMC
Corporation 
 1735 Market Street 
 Philadelphia, PA 19103 

(hereinafter referred to as “FMC”) 

and 
 Marrone Bio Innovations, Inc. 

2121 Second Street 
 Suite B-107 

Davis 
 CA 95618 

USA 
 (hereinafter referred to as “MBI”)

 Each a “Party” and collectively the “Parties” 

* * * * * * * * 
 Relating to
Biological Crop Protection Products 
 WHEREAS 
 MBI has
available the biological fungicide Regalia Maxx 20% for agricultural uses. 
 FMC and its Latin America Affiliates (collectively, the “FMC
Group”) have a broad crop protection product portfolio and a highly developed distribution network in certain LATAM Countries; 
 Gaining
access to the Commercial Product of MBI can allow FMC Group to strengthen innovative crop programs; 
 Gaining access to the FMC Group’s
distribution network and sales and marketing expertise can provide a unique possibility for MBI to reach the certain markets in certain LATAM Countries. 
 NOW
THEREFORE, the Parties agree as follows: 

 1.      Definitions, Interpretations and Exhibits 

In this Commercial Agreement (including the preamble) the following capitalized terms shall have the meanings assigned to them below: 

 

			
	“Affiliate”	  	 any business entity which controls, is controlled by or is under common control with either Party; for the purpose of this definition, a business entity shall be
deemed to “control” another business entity if it owns, directly or indirectly, in excess of 50% of the outstanding voting securities or capital stock of such business entity or any other comparable equity or ownership interest with
respect to a business entity other than a corporation;

		
	“Business Plan”	  	is an agreed to document outlining the target markets and sales targets based on an agreed development and Registration Plan and is attached hereto as Exhibit 1;
		
	“Commercial Agreement”	  	shall mean this supply, distribution and development agreement for the Commercial Product signed between the Parties;
		
	“Commercial Product”	  	 shall mean the biological product commonly known as Regalia Maxx 20% as well as any enhancement to the formulation which includes the biological component
Reynoutria sachalinesis specifically developed and being commercialized in the Field in the Territory subject to the provisions in Section 10.8;

		
	“Delivery Date”	  	 shall mean the date on which MBI is to deliver product to the applicable FMC Affiliate at the nearest US port of departure;

		
	“Effective Date”	  	shall mean August 26, 2011;
		
	“Exclusivity”	  	shall mean the exclusive commercial rights for the Commercial Product in the Field in the Territory granted from Effective Date of the Commercial Agreement by MBI to FMC;
		
	“Field”	  	shall mean the use of Commercial Product for foliar agricultural and ornamental uses as specified in Exhibit 7;
		
	“Force Majeure”	  	 shall mean blockade, civil commotion, earthquake, explosion, fire, flood, general army mobilization, insurrection, lightning, revolution, riot, sabotage, storm,
war (declared or undeclared) and any similar cause which is not reasonably within the control of the Party affected. For the avoidance of doubt, events and circumstances within each Party’s responsibility, such as breakdown of a plant due to
inability to hire sufficient and qualified staff shall not be deemed to constitute Force Majeure;

		
	“Forecast”	  	shall mean an [*****] rolling forecast as further described in Exhibit 4;

  

	[*****]	Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

  
 2 

			
	“Good Faith”	  	All negotiations between the parties have to be led in good faith;
		
	“LATAM”	  	Latin America region, to be further defined in Territory below;
		
	“Milestone Payments”	  	 shall mean payments from FMC to MBI upon reaching milestones in preparation of the Registration of the Commercial Product as well as post registration goals, as
further described herein.

		
	“Order”	  	 shall mean a written and binding order for the purchase of Commercial Product;

		
	“Party”	  	shall mean any one of the parties hereto and “Parties” shall mean both of them;
		
	“Premixes”	  	 shall mean any combination of (1) Regalia Maxx or any component such as Reynoutria sachalinesis with (2) any other biological or chemical
compound

		
	“Registration Plan”	  	Plan detailing the timing and scope of registrations for countries within the Territory as defined in Exhibit 1;
		
	“Specifications”	  	 the technical and quality specifications for the Commercial Product set forth in Exhibit 3, as amended from time to time by agreement in writing between the
Parties hereto. The Specifications shall adequately describe the physical and chemical properties (such as particle sizes) of the Commercial Product, as well as a commercially acceptable minimum shelf life and efficacy. The Parties acknowledge that
Exhibit 3 shall also contain the testing method for ascertaining compliance of the Commercial Product efficacy;

		
	“Territory”	  	shall mean certain LATAM Countries as further specified in Exhibit 6;
		
	“USD”	  	shall mean United States Dollars.

 The Section headings contained in this Commercial Agreement are for reference purposes only and shall not affect
in any way the meaning or the interpretation of this Commercial Agreement. 
 The Exhibits shall constitute an integral part of this Commercial
Agreement. In the event of any conflict between any of the Exhibits and the Commercial Agreement, the Commercial Agreement shall prevail. 

 2.    Purpose and Commitment 

2.1 Subject to the terms and conditions set forth herein, MBI intends to collaborate in researching, developing and registering the Commercial
Product and FMC on behalf of itself and its FMC Group Affiliates intends to collaborate in evaluating, marketing and selling the Commercial Product in certain LATAM Countries 

2.2 Subject to the terms and conditions set forth herein, the FMC Group will be the exclusive distributor of the Commercial Product for use in the Field in the
Territory and MBI will exclusively supply the Commercial Product for use in the Field in the Territory to the FMC Group. 
 2.3 FMC (through
itself and its FMC Group Affiliates) is committed to invest a minimum amount of [*****] from 2011 through 2013 to prepare the platform for the launch of the Commercial Product. These amounts are separate from and are in addition to the payments
listed in Exhibit 2. For the avoidance of doubt, expenditures constituting such minimum investment shall include but not be limited to FMC Group internal staff man-hours assigned to evaluate, market and sell the product, including reasonable
overhead, as well as out-of-pocket costs incurred in engaging third parties on development, marketing, and associated launch activities, as well as any fees or approvals needed for FMC Group to launch the Commercial Product. FMC shall update MBI
quarterly on its launch efforts, provided, however, that this update shall not include any right to audit FMC Group’s expenditures. 

3.    Exclusive Distribution 

3.1 Subject to the terms and conditions hereof (and the exceptions regarding Eurofert S.A referred to below), MBI agrees to sell exclusively to
FMC and its LATAM Affiliates the Commercial Product for use in the Field in the Territory, and FMC, on behalf of itself and its LATAM Affiliates, agrees to purchase all of its requirements of the Commercial Product from MBI and distribute the
Commercial Product for use in the Field in the Territory. MBI represents and warrants that it has not granted any distribution rights for the Commercial Product in the Field in the Territory to any third party, with the exception of rights granted
to Eurofert S.A. to sell “Milsana”, a [*****] formulation of Reynoutria sachalinesis, in Ecuador. To the extent FMC or its LATAM Affiliate desires to negotiate with Eurofert S.A. regarding a transfer of registration, FMC will bear
all costs associated with that effort; if that registration is not transferred, FMC agrees that MBI may continue to sell Milsana in the current [*****] formulation to Eurofert for sale and use only in Ecuador. 

3.2 FMC Group shall use commercially reasonable efforts to develop sales and achieve targets agreed in the Business Plan attached hereto as Exhibit 1. At least
once a year, FMC shall provide an updated Business Plan to MBI, which shall address annual target volumes and shall be subject to approval by MBI. 
 3.3 If in
each country in the Territory and after the 3rd year of registration of a product in such country, MBI shall have the right to appoint additional distributors (with non-exclusive distribution
rights should FMC still be committed to selling the product) should FMC or any of its relevant LATAM Affiliates fail, for any given country in the Territory, to purchase at least [*****] of the annual volume targets set forth in the Business Plan.
Both parties acknowledge that these annual targets must have reasonable accommodation for weather, macroeconomic market conditions, and competitive and regulatory dynamics which might alter FMC’s assumptions and be out of FMC’s control.

  

	[*****]	Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

  
 4 

 3.4 FMC Group shall at all times under this Commercial Agreement be regarded as an independent contractor and shall
purchase the Commercial Product on its own account for resale to third parties. 
 4.    Exclusive Supply 

4.1 FMC shall submit to MBI [*****] rolling Forecast. FMC (through itself or its LATAM Affiliates) has the obligation to purchase the volumes in
the first [*****] of the Forecast. For months [*****] of the Forecast, FMC (through itself or its LATAM Affiliates) agrees to purchase the monthly Forecast volume [*****] each month. [*****] of the Forecast are non-binding and indicative only. The
rolling Forecast submitted shall be confirmed by MBI within 10 working days after receipt, and MBI commits to supply the Forecast volumes as specified for the [*****], and for months [*****] MBI will make commercially reasonable efforts to supply
the volume of up to [*****] above the Forecast volume in each of those months. Should FMC require more than 120% in those months, the Parties will discuss a strategy for meeting FMC demand. 

4.2 All Orders shall be governed exclusively by the terms and conditions of this Commercial Agreement, and any terms or provisions on any FMC Order forms or MBI
purchase acknowledgements that are inconsistent with those contained in this Commercial Agreement shall have no force or effect whatsoever as between the Parties. Neither MBI’s commencement of performance nor delivery shall be deemed or
construed as acceptance of FMC’s additional or different terms and conditions. Orders may be sent by facsimile transmission or email or, if approved by MBI, other electronic media and shall set forth the exact quantity of Commercial Product
required and the requested Delivery Date which shall be no less than 60 days from Order date unless approved by MBI in writing. Provided that each Order is given in accordance with this Commercial Agreement (including the Forecast numbers delivered
pursuant to Section 4.1), the requested Delivery Date shall be binding on MBI, with the understanding that MBI shall still follow its usual procedure to issue an order acknowledgement for each order. 

4.3 Subject to the terms and conditions hereof, MBI shall manufacture (or have manufactured) and supply to FMC the Commercial Product in bulk.
Such Commercial Product shall, upon delivery, meet the Specifications and be in compliance with all regulatory requirements applicable in the relevant country. The Commercial Product shall be supplied to FMC or its Affiliate in the Territory
according to the Orders submitted by FMC or its Affiliate in the Territory and the terms of this Commercial Agreement, FAS delivery to the nearest US port of departure identified by FMC in accordance with Incoterms 2010 (as published by the
International Chamber of Commerce), unless stated otherwise in Exhibit 5. The FMC Group Affiliate shall have fifteen (15) days following receipt of each shipment of the Commercial Product at the FAS point in which to notify MBI in writing of
any discrepancies in such shipment as to quantity, quality, weight, loss or damage to the Commercial Product or conformity to the Specifications. Such FMC written notice to MBI shall specify in reasonable detail the nature and basis of the claim and
cite relevant control numbers or other information to enable identification of the shipment in questions. MBI shall use commercially reasonable efforts to correct such discrepancies after being so notified. If FMC Group entity fails to give such
written notice within fifteen (15) days, such shipment of Commercial Product will be deemed accepted. 
 4.4 MBI shall supply such
quantity of Commercial Product to FMC Group as FMC Group entities may order, subject to the maximums in the binding Forecasts, in accordance with the terms of this Commercial Agreement. MBI shall make available the required production capacity at
MBI’s facility or a facility of a third party to comply with FMC’s Orders and the requested Delivery Date for the Commercial Product. In the event that FMC requires additional volumes above the agreed Forecast, with respect to Commercial
Product supplied, MBI shall use commercially reasonable efforts to supply such volumes, but shall not have any obligation 

  

	[*****]	Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

  
 5 

 
to fill any Order to the extent that it exceeds one hundred and twenty percent (120%) of the forecasted orders for such Commercial Product as set forth in the Forecast. 

4.5 MBI shall inform FMC immediately when it becomes aware of a possible delay in the supply of Commercial Product. In such case the Parties
shall jointly discuss possible solutions to minimize damages caused through late delivery. 
 4.6 Both Parties shall comply at all times with
applicable law regarding the delivery, storage, production, supply etc. of the Commercial Product in accordance with Responsible Care Standards of the American Chemistry Council (current version attached as Exhibit 10). 

4.7 Transfer of full title as well as risk of loss or damage to the Commercial Product shall occur in accordance with the chosen Incoterm
(Incoterms 2010) as specified in this Section 4. 
 4.8 FMC and its Affiliates shall have complete discretion subject to the terms of this Commercial
Agreement in the commercialization of products including price, promotion, distribution channels including sub distribution to 3rd parties in the Field in the Territory. 

5.    Price and Payment 

5.1 The price per unit at which FMC Group may purchase Commercial Product are set forth on Exhibit 5. All prices are in United States Dollars.
Commencing in 2012 (or in the first year of Commercial Product sales, if later), the price may be adjusted [*****] by mutual agreement of the Parties, before [*****]. Price adjustment shall begin with the adjustment of the initial price and will
continue for the duration of the Commercial Agreement. The Parties shall meet and discuss such revised prices in good faith. 
 5.2 MBI shall
invoice the relevant FMC Group entity which places the order for each delivery made. Payment for each delivery shall be made by the relevant FMC Group entity to MBI and shall be due [*****] of delivery. Notwithstanding the foregoing, in the event
that any such payment is not fully and timely made in accordance with this Agreement, then such failure to pay shall be deemed a material breach of this Agreement by FMC, and FMC shall be fully liable for such breach in the same manner and to the
same extent as if the purchase had been made by FMC itself and such payment was originally owed by FMC, and MBI shall have full recourse hereunder to FMC for the full amount of such payment. If such breach becomes the subject of litigation, FMC
Corporation shall waive any defence related to the corporate identity of the purchaser being an FMC Group entity rather than FMC itself. 

6.    Product Registration and Milestone Payments 

6.1 Subject to the terms and conditions hereof, MBI shall use its commercially reasonable efforts to register the Commercial Product for use in [*****]. FMC
Group entities will assist MBI in registering products in [*****] and will lead registration efforts in [*****] as well as in other countries in the Territory all in accordance with the Registration Plan. MBI will work with FMC Agroquimica do Mexico
to have the Mexican registration transferred to FMC Mexico. FMC and MBI shall meet at least once annually, or more frequently as needed, to expedite registrations, to update the status of registrations in all relevant countries (the
“Registration Plan”). FMC Group entities shall be responsible for registering the Premix products detailed in the Development Plan described in Article 10 below. 

  

	[*****]	Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

  
 6 

 6.2 Subject to the terms and conditions hereof, the Parties shall be obliged to use commercially reasonable efforts
to obtain and maintain registrations of the Commercial Product, in accordance with the Registration Plan in the Business Plan, until the expiration or termination of this Commercial Agreement. In consideration of the exclusive distribution rights
hereunder, FMC and its LATAM Affiliates shall pay for the regulatory expenses, trial expenses and studies related to the labels for all countries in the Territory including additional trials required in [*****] and Mexico for label expansion. MBI
shall solely own or through its agents own, such Commercial Product registrations except as may be otherwise provided in this Commercial Agreement. 
 6.3
Subject to full and timely satisfaction of the conditions described on Exhibit 2, FMC shall pay Milestone Payments to MBI. These payments shall be made in consideration of the upfront costs already incurred by MBI and for the Exclusivity granted to
FMC and its LATAM Affiliates under this Commercial Agreement. 
 6.4 FMC Group entities may be consulted on the registration approach for registering the
Commercial Product. FMC Group entities will assist MBI in the registration process where agreed according to the Registration Plan. MBI may be consulted on registration approach for registering the Commercial Product in those countries where an FMC
entity is the lead party and MBI will assist that FMC Group entity in the registration process where agreed according to the Registration Plan. 
 6.5
    Development plans for standalone Commercial Product on [*****]  
 In addition to FMC’s work in developing Premixes as
provided in Article 10 and in addition to the existing foliar uses identified on Exhibit 7, FMC has presented MBI with an opportunity analysis for developing use of standalone Commercial Product for use in addressing: (a) [*****] and
(b) [*****] in the Territory. FMC (though itself and its LATAM Affiliates) proposes to test the Commercial Product to validate assumptions related to efficacy, use rates and overall positioning in these areas. 

MBI has considered FMC’s analysis and is willing to allow FMC and its LATAM Affiliates to pursue such development of these new uses in the identified
regions for the standalone Commercial Product on an exclusive basis subject to the terms and conditions hereof. FMC and its LATAM Affiliates will maintain development exclusivity for these uses in these countries in the Territory as long as it is in
full and timely compliance with the following: 
 1) - FMC continues to diligently develop the product and market applications 

2) - FMC submits an application for registration in at least one country with regard to [*****] with respect to [*****] after the first season of field data that
show that the Commercial Product is effective enough for submission, if allowed by the Regulatory authority of each country contemplated in this Section 6.5. 

3) - FMC agrees (with MBI) to annual purchase targets after the second season of effective field trials or when the registration is granted, whichever is later.

 If FMC’s assessment of the first season of field data leads FMC to conclude that it does not wish to submit the registration per clause 2 above, but
still wishes to continue testing and maintain exclusivity for these markets, then MBI will submit the registration and FMC will reimburse MBI for their costs. 

FMC will report at least annually on its development efforts hereunder and present summary trial data of any field trials. All data collected and summarized on
field trials will be made available to MBI. 

  

	[*****]	Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

  
 7 

 Should FMC fully comply with this Section 6 and decide to pursue registration and commercialization of the uses
referred to herein, such uses shall be automatically added to the uses listed on Exhibit 7, and FMC shall have the right to register and sell Commercial Product for such uses in a manner as provided under, and subject to the terms and conditions of,
this Commercial Agreement. Further, if FMC develops the Commercial Product for use on [*****], FMC Group’s rights to such use shall extend to other [*****] producing countries in the Territory under, and subject to the terms and conditions of,
this Commercial Agreement. 
 Should the field trials instead indicate that there exists no viable commercial outlook for either of the uses in the above
identified areas, FMC will promptly terminate its development and at that time MBI will have the right to appoint additional developers or distributors of Commercial Product in the Territory for these two uses. MBI agrees that, for so long as
FMC’s termination as per the previous sentence was principally for MBI’s proposed supply price-related reasons, such separate distribution shall not have pricing which is more favourable than that presented to FMC Group and, further, in
any country where an FMC Group entity is marketing standalone Commercial Product, any such separate distribution shall be under a separate distinct trademark and that the marketing in such other crops shall not adversely and materially impact
FMC’s distribution of products under this Commercial Agreement. 
 6.6 The Parties agree that given the unknowns in the registration process in much of
the Territory, and restrictions and limitations imposed by many countries, FMC Group and MBI technical and commercial people will regularly discuss in Good Faith options to obtain the desired registrations of the Commercial Product and Premixes, and
the Parties will amend the Business Plan and the Registration Plan and this Commercial Agreement as necessary or appropriate to achieve the fastest and most complete registration. Should ownership or title of registrations in a Party’s name (or
in both Parties’ names) as provided above prove difficult or unobtainable due to the law or practice of a particular jurisdiction, the Parties agree to work together in good faith to seek to establish relationships or mechanisms to approximate
such ownership or title to the best of their ability, including the right of the relevant Party or Parties to maintain or obtain such ownership or title upon expiration or termination of this Commercial Agreement. This may include establishing or
contracting with local entities as necessary or appropriate. Without limitation to the foregoing, in some jurisdictions it may be necessary or desirable for registrations otherwise to be owned by MBI hereunder, instead to be in the name of FMC, an
Affiliate of FMC or some local entity that may or may not be affiliated with FMC Group. In such event, the Parties agree that such registrations shall nonetheless be transferred to MBI upon MBI’s request or otherwise relinquished upon
MBI’s request and such transfer of registrations will be made in a timely manner. 
 7.    Trademarks 

7.1 The Parties intend to market the Commercial Product under the MBI trademark “REGALIA” to the extent such mark is available in
various countries in the Territory. MBI will register and solely own “REGALIA” in the various countries in the Territory if such mark is available, and shall be responsible for all reasonable costs associated with such registration. If the
trademark “REGALIA” is not available in any country in the Territory, the Parties shall consult and review potentially available alternative marks, including consideration of FMC-owned available marks. FMC will propose such trademarks for
the Commercial Product to MBI, and MBI shall have one month to approve or object to FMC’s proposal. Keeping silent shall mean consent. MBI will not withhold its approval without material reason. In those countries where the trademark
“REGALIA” is not available and where MBI has not created or registered alternative trademarks, FMC will have the right to create its own trademarks, subject to approval by MBI. FMC will be responsible for creating, and shall own,
trademarks related to Premix products. 

  

	[*****]	Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

  
 8 

 7.2 Upon receiving the bulk Commercial Product, FMC Group entities shall be responsible for printing
and affixing the labelling on the end-use packed Commercial Product in accordance with the applicable rules for labelling and Registration as well as in accordance with the applicable national laws. MBI’s company name will be listed on the
package to the extent allowed in accordance with national regulations. 
 7.3 MBI represents that, to the best of its knowledge, the existing
trademark “REGALIA” is owned by MBI in Mexico and does not infringe the rights of any other mark in the Field in Mexico. With regard to any claims of infringement of third party trademarks by MBI’s “REGALIA” trademark in
Mexico, MBI agrees to indemnify and hold harmless FMC Group entities against all claims and liabilities in Mexico (including all costs incident to any suit and judgment including reasonable attorney’s fees and investigation cost) arising from
such infringement; provided that any such indemnification is contingent upon (a) FMC Group entity giving prompt written notice to MBI of any relevant claim, action or demand, (b) FMC Group entity allowing MBI to control the defence through
an attorney reasonably satisfactory to FMC Group entity, and related settlement negotiations, and (c) FMC Group entity fully assisting in the defence so long as MBI pays FMC Group entity’s out-of-pocket expenses; and provided, further,
that nothing in this Commercial Agreement shall limit MBI’s ability to enter into any license or other agreement as necessary to make any trademark non-infringing or modify any trademark so as to be non-infringing (and to replace any trademark
otherwise used hereunder). 
 7.4 FMC Group shall promptly bring to the attention of MBI any improper or wrongful use of any of the trademarks
in the Territory that comes to its notice. 
 7.5 Trademarks, service marks or any trade secrets or proprietary information of any kind that
are proprietary to one of the Parties are and shall forever remain the sole property of that Party, and may not be used by the other for any purpose other than carrying out its responsibilities hereunder. 

7.6 FMC Group shall sell the Commercial Product in the packaging and with the labels as chosen by MBI and under the trademarks of MBI. MBI shall
use commercially reasonable efforts to assist FMC Group in assuring that the packaging and labels of the Commercial Product conforms to the Commercial Products’ Registration and all applicable laws and regulations in the Territory. 

8.    Intellectual Property 

8.1 Each Party’s rights in its intellectual property shall not be affected by the Commercial Agreement unless otherwise specified herein. 

8.2 Subject to the terms and conditions set forth herein, MBI retains all copyright, patent, trade secret, trademark rights and other intellectual property
rights in and to the Commercial Product. Nothing in this Commercial Agreement is intended to create ownership by FMC Group in the intellectual property rights of MBI. 

8.3 The Parties agree that all intellectual property rights involving the Commercial Product and its active ingredients alone shall be owned by
MBI. The Parties further agree that intellectual property involving Premixes developed pursuant to Section 10 shall be owned by FMC, except to the extent MBI owns a patent or other intellectual property on such combination, in which case MBI
hereby grants FMC a royalty free license to such MBI intellectual property for use in the Field in the Territory; provided, however, that nothing herein shall impair or transfer any intellectual property rights MBI has in the Commercial Product. FMC

  
 9 

 
hereby grants MBI a royalty free license to use FMC’s intellectual property in any such Premixes outside of the Field in the Territory and outside of the Territory. 

9.    MBI Liability 

9.1 MBI agrees to hold harmless and indemnify FMC Group entities against all claims and liabilities (including all costs incident to any suit and
judgment including without limitation reasonable attorney’s fees and investigation cost) made against FMC Group entities as a result of (i) MBI’s noncompliance with any applicable law relating to the performance by MBI of the supply
of Commercial Product hereunder (ii) MBI’s breach of the terms of this Commercial Agreement; except where and to the extent caused by a FMC Group entity’s gross negligence or wilful misconduct and except for any individual claim or
group of claims where damages sum up to less than [*****]. 
 9.2 The obligation to provide indemnification in Section 9.1 is contingent
upon (a) the indemnified party giving prompt written notice to the indemnifying party of any such claim, action or demand, (b) the indemnified party allowing the indemnifying party to control the defence through an attorney reasonably
satisfactory to the indemnified party, and related settlement negotiations, and (c) the indemnified party fully assisting in the defence so long as the indemnifying party pays the indemnified party’s out-of-pocket expenses. 

9.3 Except for a Party’s breach of the intellectual property rights under Section 8 or the confidentiality obligations under
Section 12 or gross negligence or wilful misconduct, neither Party shall have any liability, whether based in contract or tort, for any punitive, exemplary, consequential, special, indirect or incidental loss of profits or interruption of
business, arising from or related to this Commercial Agreement. 
 9.4 Other than as specifically set forth in this Commercial Agreement, MBI
makes no warranty, express or implied, with respect to the Commercial Product. 
 10.  Development – Premixes and New
Formulations 
 10.1 During the term of this Commercial Agreement, and subject to the provisions of this Article 10, FMC shall have exclusive right to
develop Premixes in the Field in the Territory. FMC will make proposals for developing Premixes in the Territory. FMC Group shall lead the development program of new products in collaboration with MBI and with reasonably necessary support from MBI.
Both parties acknowledge that new product development is subject to multiple risks and there is no guarantee for success. 
 10.2 MBI shall supply reasonable
quantities of Reynoutria sachalinesis free of charge to FMC for development of the Premixes in the Territory and Field. The price for commercial volumes of Reynoutria sachalinesis will be determined when the Premixes are near their
development completion according to Exhibit 8; the parties shall also agree on specifications for such commercial Reynoutria sachalinesis (if different from Commercial Product) which shall be added as an appendix hereto. 

10.3 FMC shall report to MBI on its development program (as described in Exhibit 8, the “Development Plan”) at least once per year. Such reporting
shall include updates on project status and a summary of any trial reports since the last report as well as a general plan for the upcoming period. 
 10.4 FMC
will be responsible for registration and regulatory study expenses and work associated with the Premixes it develops under the Development Plan, and FMC (or its relevant 

  

	[*****]	Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

  
 10 

 
LATAM Affiliate) shall own all data and registrations associated with the Premixes; provided, however, that nothing herein shall impair or transfer any intellectual property rights MBI has in the
Commercial Product. 
 10.5 Upon registration of a Premix, FMC Group shall purchase its entire requirements of Reynoutria sachalinesis for use in such
Premix from MBI and such purchases shall be made hereunder under a price and specifications to be agreed by the Parties. All purchase and sale of such Reynoutria sachalinesis shall be according to the terms and conditions of this Commercial
Agreement. 
 10.6 FMC shall complete the first Development Plan for Premixes with detail of Premix concepts within one year of the execution of this
Commercial Agreement. 
 10.7 Should a Premix concept be in the Development Plan for 3 consecutive years without any development action, MBI shall have the
right to withdraw FMC Group’s rights to exclusively develop that Premix concept and appoint another developer for the Premix in that specific segment or country in the Territory. 

10.8 FMC Group will have access during the term of the Commercial Agreement to any formulation improvements made by MBI to the Commercial Product if registration
thereof is planned by MBI for the Field and Territory. All expenses for registering any such new formulations will be borne by FMC Group. For the avoidance of doubt, and as an example only, if MBI should determine that a different percentage of
Reynoutria sachalinesis should be an effective commercial product (i.e., other than [*****] concentration) if registration thereof is planned for the Field and Territory by MBI then such new formulation shall be provided to FMC exclusively in
the Field in the Territory and subject to the terms and conditions of this Commercial Agreement. 
 10.9 In addition, MBI grants FMC the right to make
formulation improvements to the Commercial Product, subject to MBI’s prior approval and protocols to be set forth in the Development Plan. MBI retains sole right to determine if these improvements will be included in any Commercial Product. MBI
will have exclusive rights to any of these improvements for regions outside the Territory and fields outside the Field. 

11.  FMC Responsibilities and Liability 

11.1 FMC Group shall market, sell and distribute the Commercial Products at FMC Group’s risk and on FMC Group entity’s own account. In
correspondence and other dealings relating directly or indirectly to the sale or other disposition of the Commercial Products, FMC Group shall indicate that it is acting on its own account. 

11.2 FMC Group shall be responsible to sell and distribute Commercial Product only in accordance with the product Registrations. 

11.3 FMC agrees to hold harmless and indemnify MBI against all claims and liabilities (including all costs incident to any suit and judgment
including without limitation reasonable attorney’s fees and investigation cost) as a result of (i) FMC Group entity’s non-compliance with any applicable law relating to the performance by FMC Group entity of the terms of this
Commercial Agreement (ii) FMC Group entity’s breach of the terms of this Commercial Agreement and (iii) use of Premixes in the Field in the Territory; except where and to the extent caused by MBI’s gross negligence or wilful
misconduct and except where damages for any individual claim or group of claims sum up to less than [*****]. 

  

	[*****]	Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

  
 11 

 11.4 The obligation to provide indemnification in Section 11.3 is contingent upon (a) the
indemnified party giving prompt written notice to the indemnifying party of any such claim, action or demand, (b) the indemnified party allowing he indemnifying party to control the defence through an attorney reasonably satisfactory to the
indemnified party, and related settlement negotiations, and (c) the indemnified party fully assisting in the defence so long as the indemnifying party pays the indemnified party’s out-of-pocket expenses. 

11.5 Except for a Party’s breach of the intellectual property rights under Section 8 or the confidentiality obligations under
Section 12 or gross negligence or wilful misconduct, neither Party shall have any liability, whether based in contract or tort, for any punitive, exemplary, consequential, special, indirect or incidental loss of profits or interruption of
business, arising from or related to this Commercial Agreement. 
 12.    Confidentiality 

12.1 The Parties shall hold in strict confidence all confidential or proprietary information and data disclosed by or on behalf of the other or
its Affiliates prior to or after execution of this Commercial Agreement (collectively, “Information”) and the Parties shall not use such Information for any purpose other than the manufacture, supply and distribution of the Commercial
Product and the performance of its other duties under this Commercial Agreement. The Parties shall not disclose such Information to third parties, without the other Party’s prior approval in writing. 

12.2 The Parties shall only disclose the Information to those of its own and its Affiliates’ officers, employees, board members (and
observers under obligations of confidentiality) and consultants with a need to know for the proper performance of the duties under this Commercial Agreement and shall take all commercially reasonable steps to assure that all members of its staff to
whom disclosure is made will observe the above obligations. Neither Party shall disclose such Information to any existing or potential shareholder who is a direct competitor of the other Party. 

12.3 The above confidentiality obligations shall not apply to Information which: 

 

	 	(i)	 Parties can prove by written evidence was in its possession prior to disclosure by or on behalf of the other or its Affiliates; or

  

	 	(ii)	 on the date of first disclosure to one of the Parties by or on behalf of the other Party or its Affiliates was in the public domain or thereafter
becomes part of the public domain by publication or otherwise, except by one Party’s breach of this Commercial Agreement; or 

  

	 	(iii)	 which one of the Parties may receive from a third party, provided, however, that such information was not obtained by such third party, directly or
indirectly, from a Party to this Commercial Agreement or its Affiliates; or 

  

	 	(iv)	 which a Party may have to disclose to the competent regulatory bodies in order to obtain and/or maintain the manufacturing, distribution and other
licences and authorisations necessary for the manufacture, supply and distribution of the Commercial Product. 

 12.4 The Parties agree that
the terms of this Commercial Agreement, its exhibits and all related discussions will be treated as confidential. Provided, however, that nothing herein shall prohibit disclosure of the existence of this Commercial Agreement or its terms to existing
or potential investors or compliance with applicable securities laws. 

  
 12 

 12.5 The obligation to confidentiality shall outlive this Commercial Agreement for a term of six years to be
calculated starting from Termination or expiration of this Commercial Agreement. 
 12.6 Notwithstanding the foregoing, the Parties shall jointly issue a press
release announcing the signing of the Commercial Agreement and exclusive arrangements granted herein. Such press release shall require the mutual consent of each Party. 

13.  Term and Termination 
 13.1
This Commercial Agreement shall become effective on the Effective Date. 
 13.2 The term of this Commercial Agreement shall be ten
(10) years from the date of the first registration of the Commercial Product in any of Brazil, Argentina, or Colombia, unless terminated earlier as provided herein. 

13.3 The Commercial Agreement may be renewed for periods of an additional 2 years (each period an “Extended Term”), provided that both
parties agree in writing six months in advance of the end of the Term or any Extended Term. This Commercial Agreement shall not be terminated for failure to meet volume targets but can be modified based on the terms of Section 3.3. 

13.4 Notwithstanding the foregoing, either Party may terminate this Commercial Agreement with immediate effect by giving notice of termination to
the other Party: 
  

	 	(i)	 upon any material breach of this Commercial Agreement by the other Party which is not remedied within sixty (60) days from notification thereof;

  

	 	(ii)	 upon the other Party committing an act of bankruptcy or compounding with its creditors or being confiscated or sequestrated or nationalised or in any
other way transferred into state ownership; 

 13.5 Either Party may forthwith terminate this Commercial Agreement in writing if the other
Party has been prevented from fulfilling its obligations under this Commercial Agreement, in whole or in part, for more than one hundred eighty (180) days due to a Force Majeure event. 

13.6 Upon the expiration or termination of this Commercial Agreement, any Registrations to be owned by MBI hereunder or jointly owned by MBI hereunder that may
be in the name of FMC, an Affiliate of FMC or some local entity that may or may not be affiliated with FMC Group, or otherwise not in the name of MBI, shall nonetheless be transferred to MBI upon MBI’s request or otherwise relinquished upon
MBI’s request at no additional cost to MBI. 
 14.  Directly Competitive Products 

14.1 FMC shall notify MBI in writing (a) [*****] prior to any sale by a FMC Group entity in the Territory of any new product to be developed
and launched by or for FMC Group entity, or (b) promptly upon upon FMC Group entity’s acquisition of rights of any existing commerical products, where such product(s) is any biological, microbial, Induced Systemic Resistance, or plant
extract product for use in the Field in the Territory which would be directly competitive to the Commercial Product. For purposes of the foregoing, a “directly competitive” product is one whose commercialization would directly reduce the
annual target volume of the Commercial Product in that specific country by at least [*****]. Upon receipt of 

  

	[*****]	Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

  
 13 

 
such notice, and if FMC fails to meet the previously agreed volume targets in one or more countries, then MBI shall have the option, upon [*****] written notice to FMC, to re-negotiate the terms
and conditions with respect to the Commercial Product in each non-performing country and MBI shall have the option to appoint an additional distributor for that specific product in such specific country. 

15.  Force Majeure 

15.1 In the event that either Party is affected by any circumstance that prevents the fulfilment by such Party of its obligations hereunder in
whole or in part, then such Party shall notify the other Party of the nature and extent of such circumstance(s), as promptly as possible. 

15.2 Neither Party shall be deemed to be in breach of this Commercial Agreement, or otherwise be liable to the other Party, by reason of any
delay in the performance, or non-performance, of any of its obligations hereunder to the extent that such delay or non-performance is due to Force Majeure of which it has notified the other Party and the time for the performance of such obligation
shall be extended accordingly. The Party so affected shall take all reasonable steps to minimise the loss occasioned to the other Party and the Parties shall as soon as practicable enter into bona fide discussions with a view to alleviating the
effects of said circumstance or to agreeing upon such alternative arrangements as may be fair and reasonable. 
 15.3 Upon cessation of the
Force Majeure, the Party affected by Force Majeure shall resume the performance of its contractual obligation(s), as promptly as possible, unless such performance has been waived in writing by the Party to whom such performance was due. 

16.  Miscellaneous 

16.1 This Commercial Agreement shall supersede all prior oral or written agreements between MBI and FMC or its Affiliates in relation to the
subject matter contained herein. Notwithstanding the foregoing, the Material Transfer Agreement for [*****] and Mexico signed between the Parties on January 18, 2010 and July 29, 2010 shall continue. 

16.2 This Commercial Agreement may be amended only in writing signed by both Parties, and any provision of this Agreement may be waived only in
writing signed by the party waiving compliance. 
 16.3 Any assignment of this Commercial Agreement, in whole or in part, by either Party shall
require the written prior consent of the other Party, except that either Party is entitled to assign this Commercial Agreement to an Affiliate, successor in interest or purchaser of all or substantially all of its assets, provided that (i) the
assignor undertakes to inform in writing the other Party as soon as reasonably possible and (ii) the assignee undertakes in writing to be bound by the same rights and obligations as contained herein. 

16.4 All notices provided required under this Commercial Agreement shall be in the English language and in writing and shall be given by
registered letter, facsimile or e-mail to the addresses set forth below, or such other address as either Party may communicate to the other Party in accordance with this Section. A notice shall be deemed to be received upon actual receipt of a
registered letter (as evidenced by the respective receipt) or on the first business day following the date of transmission if sent by facsimile or e-mail. 

If to FMC: 

  

	[*****]	Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

  
 14 

 FMC Corporation 
 1735
Market Street 
 Philadelphia, PA 19103 

	 	Attn:	General Manger, APG 

 Group Counsel, APG 

[*****] 
 If to MBI: 

Attention: SVP Commercial Operations 
 Marrone Bio Innovations Inc. 

2121 Second St., Suite B-107 
 Davis California 95618 

United States 
 Tel 530 750 2800 

Fax 530 750 2808 
 16.5 In the event any provision of
this Commercial Agreement is deemed to be void under any applicable law, the remaining provisions of this Commercial Agreement shall not be affected and the void provision shall be deemed to have been replaced by such valid and enforceable provision
which most closely reflects the original intention of the Parties. 
 16.6 Failure of either Party to enforce at any time any of the provisions
of this Commercial Agreement, irrespective of any previous action or proceeding taken by it, shall in no way be considered: 
  

	 	(i)	a waiver of such provisions: 

	 	(ii)	to affect the validity of this Commercial Agreement; or 

	 	(iii)	to preclude or prejudice the Party from exercising the same or any other rights it may have under this Commercial Agreement. 

    17.  Governing Law and Jurisdiction 

17.1 This Commercial Agreement shall be governed and construed in accordance with the laws of the State of Delaware, excluding the principles of
conflict of laws and the United Nations Convention on the International Sale of Goods. 
 17.2 The state courts of New Castle County, Delaware
shall have exclusive jurisdiction and venue over any dispute arising out of or relating to this Agreement, and each party for itself and on behalf of its Affiliates, hereby irrevocably consents to the jurisdiction and venue of such courts. 

    18.  Taxes; Import; Export; Exchange Approvals 

18.1 All foreign, federal and state taxes based upon FMC Group entity’s purchase, use, sale, distribution or possession of the Commercial
Product, other than United States income or franchise taxes payable by MBI, will be borne and paid by the relevant purchasing FMC Group entity. MBI agrees to furnish any documents to taxing authorities if reasonably requested to do so by a FMC Group
entity. 
 18.2 FMC or its Affiliates shall be responsible for obtaining import licenses, export licenses, currency exchange approvals and any
other governmental approvals in or outside the Territory that may be necessary to permit the sale of and payment for the Commercial Product 

  

	[*****]	Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

  
 15 

 
ordered by FMC for distribution and resale within the Territory. FMC and its Affiliates shall comply with any and all laws, regulations or orders that govern or affect the ordering, export,
shipment, import, sale, deliver and redelivery of Commercial Product in the Territory and shall furnish MBI with such documentation as MBI may reasonably request to confirm FMC’s compliance with the provisions of this Section 18. Neither
FMC Group nor MBI shall engage in any course of conduct that would cause FMC Group or MBI to be in violations of the laws of any jurisdiction, including the US foreign corrupt practices act. 

                        
                [The remainder of this page is left intentionally blank.] 

  
 16 

					
	Davis, CA, USA	 		 	Philadelphia, PA, USA
			
	Marrone Bio Innovations, Inc.	 		 	FMC Corporation
			
	/s/ Pam Marrone	 		 	/s/ Marty Kisliuk
	Pamela Marrone	 		 	
	President and CEO	 		 	(title)
			
		 		 	Director of Global Operations, Business Development and M&A

  
 17 

        Exhibits to the Commercial Agreement: 

1)   Business Plan 
 2)   Milestone
Payment Plan 
 3)   Commercial Product Specifications 

4)   Eight quarters rolling forecast model (empty) 

5)   Pricing & Packaging 

6)   List of LATAM Countries 
 7)   List
of Agricultural Crops 
 8)   Development Plan for Premixes 

9)   Pricing for Premixes 
 10) Responsible Care
Standards 

  
 18 

 Exhibit 1: Business Plan 

Business Plan is defined by country/crop/pest segment and includes: 

a) Price 
 b) Volumes 

c) Assumptions 
 d) Potential
Opportunities 
 e) Premix Development Plans 

f) Registration Plan 
 [*****]

  

	[*****]	Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

  
 19 

 Exhibit 2: Milestone Payment Plan 

Date targets below are only estimates. Payment amounts are fixed. 

a)    Milestone Payment Plan 

All milestones to be paid by wire transfer to MBI upon the timely and full completion of the relevant milestone event. 

1.    Milestone 1:  

Signing of this agreement [*****] – payable within two weeks 

2.    Milestone 2 (Target date 2012):  

 [*****]  

3.    Milestone 3 (Target date 2013):  

[*****] 

4.    Milestone 4:  

[*****] 

5.    Milestone 5 (Target date 2014): 

[*****] 

6.    Milestone 6 (Target date, 2016):  

[*****] 

  

	[*****]	Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

  
 20 

 Exhibit 3: Commercial Product Specifications – Regalia MAXX 20% 

[*****] 
 See attached document for method. 

In the event FMC shall register and market other formulations of Commercial Product in any country in the Territory in accordance with the terms
and conditions of Section 10.9 of this Commercial Agreement, prior to such commercialization the Parties shall agree on specifications for such other formulation(s) which shall be deemed incorporated herein. 

  

	[*****]	Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

  
 21 

 Exhibit 4: Initial Eight Quarters Rolling Forecast Model 

[*****] 

  

	[*****]	Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

  
 22 

 Exhibit 5: Pricing & Packaging 

Price: 
 [*****] includes shipping, taxes, duties delivered
to Mexico location of FMC 
 Rest of countries in Exhibit 6 USD [*****] 

Packaging: Product will be supplied in bulk 

  

	[*****]	Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

  
 23 

 Exhibit 6: List of LATAM Countries (the “Territory”) 

1.    Mexico 
 [*****]

  

	[*****]	Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

  
 24 

 Exhibit 7: List of Agricultural Crops (“Field”) 

Foliar applications: 
 [*****]

 FMC shall have the right to add other crops to the listed crops above, subject to first presenting a Business Plan and obtaining MBI’s
approval, which shall not be unreasonably withheld. 
 Further, MBI agrees that it shall not provide distribution rights for foliar
applications of the Commercial Product to another distributor for any crop not listed in this Exhibit 7 in any country in the Territory unless MBI first gives FMC a right of first refusal which FMC must exercise within 60 days of notification. MBI
agrees that such separate distribution shall not have pricing which is more favorable than that presented to FMC and shall be under a separate distinct trademark and that the marketing in such other crops shall not adversely and materially impact
FMC’s distribution of products under this Commercial Agreement. 

  

	[*****]	Confidential portions of this document have been redacted and filed separately with the Securities and Exchange Commission 

  
 25 

 Exhibit 8: Development Plan for Premixes (the “Development Plan”) 

Will be developed within one year of signing the agreement. 

  
 26 

 Exhibit 9: Pricing for Premixes 

To be determined. 

  
 27 

 Exhibit 10: Responsible Care Standards 

Our industry creates products and services that make life better for people around the world — both today and tomorrow. The benefits of our industry are
accompanied by enduring commitments to Responsible Care® in the management of chemicals worldwide. We will make continuous progress toward the vision of no accidents, injuries or harm to the
environment and will publicly report our global health, safety and environmental performance. We will lead our companies in ethical ways that increasingly benefit society, the economy and the environment while adhering to the following principles:

  

	 	•	 	        To seek and incorporate public input regarding our products and operations. 

  

	 	•	 	        To provide chemicals that can be manufactured, transported, used and disposed of safely. 

 

	 	•	 	        To make health, safety, the environment and resource conservation critical considerations for all new and existing products and processes. 

 

	 	•	 	        To provide information on health or environmental risks and pursue protective measures for employees, the public and other key stakeholders. 

 

	 	•	 	        To work with customers, carriers, suppliers, distributors and contractors to foster the safe use, transport and disposal of chemicals. 

 

	 	•	 	        To operate our facilities in a manner that protects the environment and the health and safety of our employees and the public. 

 

	 	•	 	        To support education and research on the health, safety and environmental effects of our products and processes. 

 

	 	•	 	        To work with others to resolve problems associated with past handling and disposal practices. 

 

	 	•	 	        To lead in the development of responsible laws, regulations and standards that safeguard the community, workplace and environment. 

 

	 	•	 	        To practice Responsible Care® by encouraging and assisting others to adhere to these principles and practices.

  
 28 

 FMC implements Responsible Care as a necessary part of all supply agreements. Supplier will at least once
annually meet with FMC to discuss and confirm supplier’s performance on the following. 
 1.1. Objectives and Expectations 

	 	1.1.1.	  Protect people and the environment 

	 	1.1.2.	  Meet all local and national regulatory requirements 

	 	1.1.3.	  Minimize liabilities 

	 	1.1.4.	  Operate as a responsible neighbor and part of the community 

	 	1.1.5.	  Continuous improvement 

 1.2. Requirements for contractors 

	 	1.2.1.	  Environmental Impact Assessment Report and approval 

	 	1.2.2.	  Pesticide Production Permit (if needed under local law) 

	 	1.2.3.	  Management commitment to safety and Responsible Care principles 

	 	1.2.4.	  Annual plan for improvement and improvements are evident 

	 	1.2.5.	  Process Safety Reviews commensurate with the process risks 

	 	1.2.6.	  A Management Of Change process – prior approval by FMC 

	 	1.2.7.	  Emergency Response Plan 

	 	1.2.8.	  Worker training, including hazard recognition 

	 	1.2.9.	  Worker exposure assessment and control 

	 	1.2.10.	  Flammable liquids management 

	 	1.2.11.	  Written & maintained Operating Procedures and Safety Permits 

	 	1.2.12.	  Transportation emergency management and Hazmat response plan 

	 	1.2.13.	  Build and maintain good community relations 

	 	1.2.14.	  Preventive maintenance on critical equipment 

	 	1.2.15.	  Procedures to prevent and detect cross-contamination 

	 	1.2.16.	  Report all incidents and accident statistics 

	 	1.2.17.	  Improvement plan and implementation program 

	 	1.2.18.	  Specific accountabilities for all of the above 

	 	1.2.19.	  Documentation of all of the above 

 1.3. Tools FMC can provide contractors 

	 	1.3.1.	  Information to foster proper handling, use, recycle and disposal 

	 	1.3.2.	  Checklists 

	 	1.3.3.	  Guidelines 

	 	1.3.4.	  Recommend consultants 

  
 29 

 1.4. Evaluation and Screening of Suppliers and Contract Manufacturers 

	 	1.4.1.	    FMC will select contract manufacturers who employ appropriate practices 

	 	1.4.1.1.	    Ability and willingness to meet requirements above 

	 	1.4.1.2.	    Practices result in Acceptable Risks 

	 	1.4.2.	    Tools to use 

	 	1.4.2.1.	    Checklists 

	 	1.4.2.2.	    Risk evaluation techniques/matrix 

	 	1.4.2.3.	    Guidelines 

	 	1.4.2.3.1.	    Process Safety 

	 	1.4.2.3.2.	    Environmental 

	 	1.4.2.3.3.	    Waste Disposal 

 1.5. Audit of contractor Responsible Care compliance 

	 	1.5.1.	    Progress tracking mechanism 

	 	1.5.1.1.	    Feedback to contractor regarding progress 

  
 30

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00219-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00219-of-00352.parquet"}]]